[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 550
1. Hong SM, Kim MJ, Jang KT, Yoon GS, Cho H, Frierson HF, Yu E: Adenosquamous carcinoma of extrahepatic bile duct: clinicopathologic study of 12 cases. Int J Clin Exp Pathol; 2008;1(2):147-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of extrahepatic bile duct: clinicopathologic study of 12 cases.
  • Adenosquamous carcinoma is a rare histologic subtype of extrahepatic bile duct (EBD) carcinoma and limited information is available on its clinicopathologic characteristics.
  • Twelve cases of adenosquamous carcinoma were collected from 3 institutions and their clinicopathologic characteristics were examined and compared with those of 176 EBD adenocarcinomas.
  • The adenocarcinoma component was more often seen at the surface of the tumor (7 of 12 cases, 58%), while the squamous carcinoma component was slightly more frequent at the advanced edge (7 of 12 cases, 58%).
  • Immunohistochemistry, available in 10 cases, revealed that S100A2 was positive in the squamous carcinoma component in all 10 cases (100%), while it was present in the adenocarcinoma component in only 2 of 10 cases (20%, chi-square test, p=0.001).
  • Patients with adenosquamous carcinomas had worse survival (median survival, 11 months) than those with adenocarcinoma (median survival, 32 months; log-rank test, p=0.003).
  • Patients with predominant squamous cell carcinoma component at the leading edge had worse survival than those without it.
  • In conclusion, patients with adenosquamous carcinoma demonstrated worse survival than those with pure adenocarcinoma.
  • S100A2 immunohistochemical staining may be helpful in detecting the squamous component.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):199-206 [17255764.001]
  • [Cites] J Gastroenterol. 2000;35(6):465-71 [10864356.001]
  • [Cites] Cancer. 2005 Aug 15;104(4):802-10 [15959914.001]
  • [Cites] J Gastroenterol. 2005 Feb;40(2):192-9 [15770404.001]
  • [Cites] Dis Colon Rectum. 1999 Feb;42(2):258-63 [10211505.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 1):2309-16 [9815629.001]
  • [Cites] Diagn Cytopathol. 1996 Nov;15(4):322-4 [8982588.001]
  • [Cites] Ryoikibetsu Shokogun Shirizu. 1996;(9):61-3 [8705560.001]
  • [Cites] Nihon Kyobu Shikkan Gakkai Zasshi. 1994 Feb;32(2):161-7 [8164404.001]
  • [Cites] J Gastroenterol Hepatol. 1993 Nov-Dec;8(6):607-12 [8280849.001]
  • [Cites] J Surg Oncol. 1986 Oct;33(2):140-2 [3531727.001]
  • [Cites] Ann Thorac Surg. 1987 Nov;44(5):462-6 [3675050.001]
  • [Cites] J Surg Oncol. 1980;15(1):29-35 [7421268.001]
  • [Cites] South Med J. 1978 Feb;71(2):216-9 [622635.001]
  • [Cites] Methods Mol Biol. 2005;289:209-22 [15502186.001]
  • [Cites] Br J Cancer. 2004 Oct 18;91(8):1515-24 [15467767.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 1;322(4):1111-22 [15336958.001]
  • [Cites] Biochem Cell Biol. 2004 Aug;82(4):508-15 [15284904.001]
  • [Cites] Gastrointest Endosc. 2004 Aug;60(2):300-4 [15278069.001]
  • [Cites] Tumour Biol. 2004 Jan-Apr;25(1-2):31-40 [15192310.001]
  • [Cites] Chir Ital. 2004 Mar-Apr;56(2):289-95 [15152526.001]
  • [Cites] Gynecol Oncol. 2003 Dec;91(3):558-62 [14675676.001]
  • [Cites] Cancer. 2003 May 1;97(9):2196-202 [12712471.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6823-6 [12460893.001]
  • [Cites] Histol Histopathol. 2002 Jan;17(1):123-30 [11813862.001]
  • [Cites] Pathologica. 2000 Oct;92(5):323-6 [11198466.001]
  • [Cites] Int J Mol Med. 2000 Nov;6(5):539-42 [11029520.001]
  • [Cites] Neoplasia. 2006 Oct;8(10):843-50 [17032501.001]
  • (PMID = 18784802.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2480552
  • [Keywords] NOTNLM ; Adenosquamous carcinoma / S100A2 / cholangiocarcinoma / extrahepatic bile duct / prognosis
  •  go-up   go-down


2. Kenjo M, Uno T, Murakami Y, Nagata Y, Oguchi M, Saito S, Numasaki H, Teshima T, Mitsumori M: Radiation therapy for esophageal cancer in Japan: results of the Patterns of Care Study 1999-2001. Int J Radiat Oncol Biol Phys; 2009 Oct 1;75(2):357-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ninety-nine percent had squamous cell carcinoma histology.
  • Fourteen percent had clinical Stage 0-I disease, 32% had Stage IIA-IIB, 43% had Stage III, and 10% had Stage IV disease.
  • Squamous cell carcinoma accounted for the majority of patients.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Esophageal Neoplasms / radiotherapy. Health Care Surveys
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Aged. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Adenosquamous / surgery. Combined Modality Therapy / methods. Combined Modality Therapy / utilization. Female. Humans. Japan. Male. Middle Aged. Neoplasm Staging. Radiotherapy / methods

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19735863.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


3. Suzuki T, Suzuki T, Shinoda M, Takashi H, Yamaguchi H, Murayama M, Kamiya T, Morise K, Tashiro K, Kimura M, Yamagishi S, Ando T, Goto H: [An autopsy case of colon cancer associated ulcerative colitis complicated focal squamous cell carcinoma]. Nihon Shokakibyo Gakkai Zasshi; 2007 May;104(5):684-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An autopsy case of colon cancer associated ulcerative colitis complicated focal squamous cell carcinoma].
  • At autopsy, the histological examination showed many mucinous adenocarcinoma and signet ring cell carcinoma with dysplasia.
  • There were also some areas of squamous cell carcinoma with squamous metaplasia and dysplasia far from rectum.
  • Squamous cell carcinoma and adenosquamous cell carcinoma of the colon are rare complications of ulcerative colitis.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Colitis, Ulcerative / complications. Colonic Neoplasms / pathology
  • [MeSH-minor] Adult. Carcinoma, Adenosquamous / pathology. Carcinoma, Signet Ring Cell / pathology. Female. Humans. Neoplasms, Multiple Primary / pathology


Advertisement
4. Mingoli A, Brachini G, Petroni R, Antoniozzi A, Cavaliere F, Simonelli L, Chirletti P, Modini C: Squamous and adenosquamous cell carcinomas of the gallbladder. J Exp Clin Cancer Res; 2005 Mar;24(1):143-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous and adenosquamous cell carcinomas of the gallbladder.
  • Squamous and adenosquamous cell carcinomas (ASC and SCC) are rare subtypes of gallbladder cancer, traditionally considered more aggressive and with a poorer prognosis than adenocarcinoma.
  • We report about two patients affected by an advanced squamous cell carcinoma of the gallbladder.
  • In conclusion, an aggressive and radical surgical treatment of advanced squamous and adenosquamous cell gallbladder carcinomas seems to be indicated for their low proclivity to distant spreading.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / pathology. Gallbladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943044.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 50
  •  go-up   go-down


5. Ghosh M, Kamma H, Kawamoto T, Koike N, Miwa M, Kapoor VK, Krishnani N, Agrawal S, Ohkohchi N, Todoroki T: MUC 1 core protein as a marker of gallbladder malignancy. Eur J Surg Oncol; 2005 Oct;31(8):891-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: The significance of MUC 1 expression in the gallbladder tissues in relation to cancer and non-cancer disease is not well understood.
  • MATERIALS AND METHODS: A monoclonal antibody (CA 15--3; DF 3) was applied to stain MUC 1 core protein in surgical specimens.
  • Every cell of normal and inflammatory mucosa, and T1 cancers had the polarized pattern.
  • CONCLUSION: MUC 1 core protein expression rate and pattern are suggesting that MUC 1 core protein would be a marker of malignant transformation of gallbladder epithelium and its depolarized expression would also be a marker of invasion of gallbladder cancer.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / secondary. Antibodies, Monoclonal. Antigens, Neoplasm. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / secondary. Carcinoma, Signet Ring Cell / pathology. Carcinoma, Signet Ring Cell / secondary. Cell Polarity. Cholecystitis / pathology. Coloring Agents. Connective Tissue / pathology. Gallbladder / pathology. Granuloma / pathology. Humans. Lymphatic Metastasis / pathology. Mucin-1. Mucous Membrane / pathology. Neoplasm Invasiveness. Neoplasm Staging. Serous Membrane / pathology. Xanthomatosis / pathology

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15922536.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Coloring Agents; 0 / Glycoproteins; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / Mucins
  •  go-up   go-down


6. Kawano R, Hino H, Hoshino T, Yokota T, Ikeda S, Hata E: [Primary lung cancer protruding into right main bronchus, successfully treated with endoscopic neodymium yttrium aluminum garnet (Nd-YAG) laser]. Kyobu Geka; 2009 Aug;62(9):807-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 67-year-old male patient with a chief complaint of cough and sputum had a primary lung cancer (squamous cell carcinoma) in the upper lobe of the right lung.
  • [MeSH-major] Bronchi / pathology. Bronchoscopy. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / surgery. Laser Therapy / methods. Lung Neoplasms / pathology. Lung Neoplasms / surgery

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19670784.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


7. Jamali M, Serra S, Chetty R: Adenosquamous carcinoma of the pancreas with clear cell and rhabdoid components. A case report. JOP; 2007;8(3):330-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the pancreas with clear cell and rhabdoid components. A case report.
  • CONTEXT: In as much as no such variant of this pancreatic tumour has been previously reported in the literature, we report an unusual case of an adenosquamous carcinoma of the pancreas characterized by clear cells and rhabdoid cells.
  • Endoscopic retrograde pancreatography showed mild to moderate dilatation of the intrapancreatic biliary tract and of the pancreatic duct, and a biliary stent was placed.
  • Histological evaluation of the pancreatic mass revealed an adenosquamous carcinoma displaying both clear cell and rhabdoid components.
  • CONCLUSIONS: Assessing the predominant histology of pancreatic adenosquamous carcinoma variants such as those characterized by clear cells and rhabdoid cells may help select and improve upon therapies in this aggressive lesion.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Pancreatic Neoplasms / pathology. Rhabdoid Tumor / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17495363.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


8. Mano H: Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. Cancer Sci; 2008 Dec;99(12):2349-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, through a functional screening with retroviral cDNA expression libraries, we have discovered the fusion-type protein tyrosine kinase echinoderm microtubule-associated protein like-4 (EML4)-anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC) specimens.
  • In the present review I summarize how detection of EML4-ALK cDNA may become a sensitive diagnostic means for NSCLC cases that are positive for the fusion gene, and discuss whether suppression of ALK enzymatic activity could be an effective treatment strategy against this intractable disorder.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Lung Neoplasms / genetics. Neoplasms / genetics. Oncogene Proteins, Fusion / genetics
  • [MeSH-minor] Carcinoma, Adenosquamous / genetics. Cell Transformation, Neoplastic. Chromosomes, Human, Pair 2. Exons. Gene Rearrangement. Humans. Male. Middle Aged. Models, Genetic. Translocation, Genetic

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19032370.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / EML4-ALK fusion protein, human; 0 / Oncogene Proteins, Fusion
  • [Number-of-references] 71
  •  go-up   go-down


9. Ikeda O, Mizukami N, Murata Y, Arakawa A, Katabuchi H, Okamoto H, Yasunaga T, Tsunawaki A, Yamashita Y: Randomized comparison of intra-arterial chemotherapy versus intra-arterial chemotherapy and gelfoam embolization for treatment of advanced cervical carcinoma. Cardiovasc Intervent Radiol; 2005 Nov-Dec;28(6):736-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized comparison of intra-arterial chemotherapy versus intra-arterial chemotherapy and gelfoam embolization for treatment of advanced cervical carcinoma.
  • Of these, 18 had stage IIb , 4 had stage IIIa, 19 had stage IIIb, and 4 had stage IVb cancer; the histopathologic types were squamous cell carcinoma (n = 35), adenocarcinoma (n = 8), and adenosquamous carcinoma (n = 2).
  • RESULTS: In groups A, B, and C, the tumor reduction ratio was 54%, 84%, and 86%, respectively; it was significantly greater in groups B and C than in group A (p < 0.01).
  • The difference between groups B and C was not statistically significant.
  • CONCLUSION: Group B and C patients had better tumor reduction than those in group A.
  • [MeSH-major] Carcinoma / therapy. Drug Therapy, Combination. Embolization, Therapeutic / methods. Gelatin Sponge, Absorbable / therapeutic use. Hemostatics / therapeutic use. Uterine Cervical Neoplasms / therapy


10. Yang GZ, Li J, Ding HY: [Nipple adenoma: report of 18 cases with review of literatures]. Zhonghua Bing Li Xue Za Zhi; 2009 Sep;38(9):614-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the clinicopathological and immunohistochemical features, diagnosis and differential diagnosis of nipple adenoma of the breast.
  • The glandular epithelium showed various type of proliferation, forming thick layers or complex structures such as papillae, micropapillae, tufts, fronds, arcades or bridges accompanying with solid or cribriform cell nests.
  • By immunostaining, the glandular epithelium was diffusely positive for 34betaE12, patchily positive for CK5/6, and negative for p53 and c-erbB-2.
  • It is easily confused with atypical ductal hyperplasia/low grade ductal carcinoma in situ, invasive ductal carcinoma or low grade adenosquamous carcinoma.
  • A correct diagnosis is based on the peculiar location and morphology of the tumor, and immunohistochemistry is helpful in some cases.
  • [MeSH-minor] Adult. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Adenosquamous / metabolism. Carcinoma, Adenosquamous / pathology. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Diagnosis, Differential. Female. Humans. Keratin-5 / metabolism. Keratins / metabolism. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20079190.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CK-34 beta E12; 0 / Keratin-5; 68238-35-7 / Keratins
  •  go-up   go-down


11. Nakajima TE, Ura T, Ito Y, Kato K, Minashi K, Nihei K, Hironaka S, Boku N, Kagami Y, Muro K: A phase I trial of 5-fluorouracil with cisplatin and concurrent standard-dose radiotherapy in Japanese patients with stage II/III esophageal cancer. Jpn J Clin Oncol; 2009 Jan;39(1):37-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Twelve patients with previously untreated clinical Stage II/III squamous cell esophageal carcinoma were studied.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Adenocarcinoma / secondary. Adult. Aged. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Adenosquamous / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / secondary. Cisplatin / administration & dosage. Combined Modality Therapy. Dose-Response Relationship, Drug. Dose-Response Relationship, Radiation. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Japan. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19103671.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


12. Kumar JV, Doval DC, Rao R, Rawal S: A retrospective study of patients with locally advanced cancer of the cervix treated with neoadjuvant chemotherapy followed by radical surgery. Int J Gynecol Cancer; 2009 Apr;19(3):417-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Percentage of patients who needed adjuvant radiotherapy and disease-free interval at 2 years was evaluated.
  • Recurrences were noted; 46.4% of patients were in stage 2b, followed by 25% in stage IIIb; 92.8% of patients had squamous cell carcinoma.
  • At 2 years, disease-free interval for 49 patients who underwent radical surgery was 69%.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / secondary. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19407570.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


13. Zhang DK, Su XD, Lin P, Long H, Fu JH, Zhang LJ, Ma GW, Rong TH: [Clinical analysis of 22 cases of esophageal adenosquamous carcinoma]. Zhonghua Zhong Liu Za Zhi; 2009 Apr;31(4):302-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 22 cases of esophageal adenosquamous carcinoma].
  • OBJECTIVE: This study was to review the clinical features, diagnosis, treatment, and prognosis of esophageal adenosquamous carcinoma (ASC).
  • Esophageal ASC showed similar clinical symptoms, radiological and endoscopic features to esophageal squamous cell carcinoma (ESCC).
  • CONCLUSION: Esophageal adenosquamous carcinoma is a rare esophageal disease and prone to be misdiagnosed as esophageal squamous cell carcinoma.
  • The prognosis of esophageal adenosquamous carcinoma has not yet been well established.
  • [MeSH-major] Carcinoma, Adenosquamous / diagnosis. Carcinoma, Squamous Cell / diagnosis. Diagnostic Errors. Esophageal Neoplasms / diagnosis. Esophagectomy / methods

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615289.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Serkies K, Jassem J, Dziadziuszko R: Chemotherapy with mitomycin c, ifosfamide, and cisplatin for recurrent or persistent cervical cancer. Int J Gynecol Cancer; 2006 May-Jun;16(3):1152-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Aged. Anemia / chemically induced. Blood Cell Count. Carcinoma, Adenosquamous / blood. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / mortality. Disease-Free Survival. Drug Evaluation. Female. Humans. Leukopenia / chemically induced. Middle Aged. Neoplasms, Squamous Cell / blood. Neoplasms, Squamous Cell / drug therapy. Neoplasms, Squamous Cell / mortality. Remission Induction / methods. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803499.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


15. Eickhoff A, Knoll M, Jakobs R, Weickert U, Hartmann D, Schilling D, Eickhoff JC, Riemann JF: Self-expanding metal stents versus plastic prostheses in the palliation of malignant dysphagia: long-term outcome of 153 consecutive patients. J Clin Gastroenterol; 2005 Nov-Dec;39(10):877-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Self-expanding metal stents versus plastic prostheses in the palliation of malignant dysphagia: long-term outcome of 153 consecutive patients.
  • BACKGROUND: Malignant dysphagia due to esophagogastric cancer is associated with poor overall prognosis.
  • RESULTS: Stent placement was successful in 41 of 45 (93%) patients of Group A and 107 of 108 (99%) of Group B.
  • Recurrent dysphagia was noted in 12 of 45 (27%) patients of Group A and 27 of 108 (25%) patients of Group B.
  • Overall complications occurred in 15 of 45 (33%) patients of Group A and 28 of 108 (26%) patients of Group B.
  • CONCLUSIONS: Our results indicate a marginal clinical benefit for metal stents versus plastic tubes in malignant dysphagia in the long run.
  • [MeSH-minor] Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / surgery. Coated Materials, Biocompatible / economics. Coated Materials, Biocompatible / therapeutic use. Cost-Benefit Analysis. Esophageal Neoplasms / surgery. Female. Follow-Up Studies. Germany. Humans. Male. Middle Aged. Prosthesis Design / instrumentation. Recurrence. Retrospective Studies. Stomach Neoplasms / surgery. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Dysphagia.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Swallowing Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16208111.001).
  • [ISSN] 0192-0790
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coated Materials, Biocompatible; 0 / Metals; 0 / Plastics
  •  go-up   go-down


16. Okudela K, Suzuki M, Kageyama S, Bunai T, Nagura K, Igarashi H, Takamochi K, Suzuki K, Yamada T, Niwa H, Ohashi R, Ogawa H, Mori H, Kitamura H, Kaneko T, Tsuneyoshi T, Sugimura H: PIK3CA mutation and amplification in human lung cancer. Pathol Int; 2007 Oct;57(10):664-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For biological validation, the effects of exogenously expressed wild-type and mutated PIK3CA were studied in an immortalized human airway epithelial cell line.
  • The prevalence of copy number gains was higher in men, smokers, and in patients with squamous cell carcinoma than in the opposite categories.
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma / genetics. Lung Neoplasms / genetics. Mutation. Phosphatidylinositol 3-Kinases / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / metabolism. Carcinoma, Adenosquamous / pathology. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / metabolism. Carcinoma, Large Cell / pathology. Carcinoma, Small Cell / genetics. Carcinoma, Small Cell / metabolism. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cell Line, Transformed. DNA, Neoplasm / analysis. Female. Gene Dosage. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Pathol Int. 2007 Nov;57(11):757
  • (PMID = 17803655.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human
  •  go-up   go-down


17. Teramoto N, Nishimura R, Saeki T, Nogawa T, Hiura M: Adenoid basal carcinoma of the uterine cervix: report of two cases with reference to adenosquamous carcinoma. Pathol Int; 2005 Jul;55(7):445-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid basal carcinoma of the uterine cervix: report of two cases with reference to adenosquamous carcinoma.
  • Adenoid basal carcinoma (ABC) of the uterine cervix is a rare neoplasm with excellent prognosis.
  • Differential diagnosis between ABC and an ABC-like lesion of adenosquamous cell carcinoma (ASC) of the cervix is important due to their contrasting prognosis.
  • The two ABC were incidentally found in the uterine cervix of 69-year-old and 59-year-old Japanese women due to cervical intraepithelial neoplasia grade 3 and to squamous cell carcinoma, respectively.
  • An ABC-like lesion was defined as basaloid cell nests simulating ABC, but with some features indicating malignant potential.
  • However, the differential diagnosis was sometimes difficult because two of seven ABC-like lesions were originally diagnosed as ABC.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Carcinoma, Adenosquamous / pathology. Carcinoma, Basal Cell / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratin-7. Keratin-8. Keratins / analysis. Ki-67 Antigen / analysis. Middle Aged

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15982222.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / KRT7 protein, human; 0 / KRT8 protein, human; 0 / Keratin-7; 0 / Keratin-8; 0 / Ki-67 Antigen; 68238-35-7 / Keratins
  •  go-up   go-down


18. Miller DS, Blessing JA, Bodurka DC, Bonebrake AJ, Schorge JO, Gynecologic Oncology Group: Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol; 2008 Jul;110(1):65-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
  • OBJECTIVE: To estimate the anti-tumor activity of pemetrexed in patients with advanced or recurrent carcinoma of the cervix that failed on higher priority treatment protocols and to determine the nature and degree of toxicity.
  • Patients must have had advanced or recurrent measurable carcinoma of the cervix, and failed one prior chemotherapy regimen.
  • The response rate for non-radiated or radiated disease sites was 25% and 7% respectively.
  • Sixteen patients (59%) had stable disease and seven (26%) patients had increasing disease.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adult. Aged. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Dexamethasone / therapeutic use. Disease Progression. Drug Administration Schedule. Female. Humans. Injections, Intravenous. Middle Aged. Neoplasm Recurrence, Local. Patient Selection. Pemetrexed. Treatment Outcome


19. Kim KW, Kim SH, Kim MA, Lee JM, Park HS, Kim JY, Lee JY, Han JK, Choi BI: Adenosquamous carcinoma of the extrahepatic bile duct: clinicopathologic and radiologic features. Abdom Imaging; 2009 Mar-Apr;34(2):217-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the extrahepatic bile duct: clinicopathologic and radiologic features.
  • BACKGROUND: To retrospectively analyze computed tomography (CT) features of adenosquamous carcinoma (ASC) of the extrahepatic bile duct and to correlate them with pathologic findings.
  • Histologically, ASC was composed of squamous and glandular components which mixed in an intermingled pattern and was characterized by a high local aggressiveness mainly due to the squamous component.
  • However, their CT findings are not quite different from those of usual adenocarcinoma due to the unique geographic characteristic of being located at a very limited space.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Duct Neoplasms / radiography. Bile Ducts, Extrahepatic. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18204917.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Molina R, Filella X, Augé JM, Bosch E, Torne A, Pahisa J, Lejarcegui JA, Rovirosa A, Mellado B, Ordi J, Biete A: CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA. Anticancer Res; 2005 May-Jun;25(3A):1765-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The serum levels of CYFRA 21.1, CEA and SCC were prospectively determined in 156 patients diagnosed with carcinoma of the uterine cervix from 1995 to 2003.
  • Histology revealed squamous cancer in 119 patients, adenocarcinoma in 25 patients and adenosquamous carcinoma in the remaining 12 patients.
  • The sensitivity of CYFRA 21.1, CEA and SCC was 26%, 25% and 43%, respectively, at diagnosis.
  • SCC was clearly related to tumor histology, with significantly higher levels in squamous tumors than in other histological types (p<0.0001).
  • Abnormal pretreatment serum levels indicated a high probability (>83%) of parametrial invasion in squamous tumors.
  • In conclusion, SCC is the tumor marker of choice in squamous tumors and the addition of CEA or CYFRA 21.1 does not significantly increase the sensitivity obtained by using SCC alone.

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16033097.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / Serpins; 0 / antigen CYFRA21.1; 0 / squamous cell carcinoma-related antigen; 68238-35-7 / Keratins
  •  go-up   go-down


21. Amălinei C, Balan R, Stolnicu S, Rădulescu D, Boeru C, Cotuţiu C: Adenosquamous cervical carcinoma morphological characteristics. Rev Med Chir Soc Med Nat Iasi; 2005 Apr-Jun;109(2):343-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous cervical carcinoma morphological characteristics.
  • Adenosquamous carcinomas range between 5-25% of cervical cancers and are composed by an admixture of malignant squamous and glandular elements.
  • Differential diagnosis with endometrioid adenocarcinoma of the cervix with squamous metaplasia was made.
  • Four cases (26.66%) were subtyped as clear cell adenosquamous carcinomas and 2 cases (13.33%) were subtyped as glassy cell carcinomas, exhibiting finely granular ground glass type cytoplasm.
  • 93.33% of cases exhibited a poorly differentiated squamous component and 66.66% of cases exhibited a well differentiated glandular component.
  • Squamous intraepithelial lesions in overlying epithelium was observed in 4 cases (26.66%).
  • One case, diagnosed as glassy cell subtype, presented regional lymph node metastases.
  • Our study concluded the occurrence of adenosquamous cervical carcinomas at a similar age with squamous cervical carcinomas in the investigated group of patients.
  • As adenosquamous cervical carcinomas are considered expressions of a biphasic differentiation of a single pluripotential sub-columnar reserve cell, a similar degree of differentiation of the two components would be expected.
  • Although, we registered a degree of variability in grading of the two components, with a tendency of squamous component toward poorly differentiated aspect and a slightly dominant aspect of well differentiated glandular pattern.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Middle Aged. Retrospective Studies


22. Gaffney DK, Winter K, Dicker AP, Miller B, Eifel PJ, Ryu J, Avizonis V, Fromm M, Small W, Greven K: Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128. Int J Radiat Oncol Biol Phys; 2007 Sep 1;69(1):111-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The overall and disease-free survival rates were determined.
  • The estimated 2-year disease-free survival and overall survival rate was 69% and 83%, respectively.
  • Of the 78 patients, 24 had treatment failure: 3 with persistent local disease, 9 local only, 2 regional, 4 distant, 1 regional and distant, 1 local and distant, and 2 with local, regional, and distant disease, and 1 had died of cervical cancer without a reported site of first failure and 1 without evidence of disease.
  • CONCLUSION: At 2 years, the estimated disease-free survival and overall survival rate for patients with advanced cervical cancer who underwent a combination of chemoradiotherapy and celecoxib treatment was 69% and 83%, respectively.
  • Recurrent disease developed in 24 patients, and, of those patients, 18 had a component of locoregional failure as a site of first failure.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CELECOXIB .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17482376.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA106633-03; United States / NCI NIH HHS / CA / R01 CA106633; United States / NCI NIH HHS / CA / R01 CA106633-01; United States / NCI NIH HHS / CA / CA106633-02; United States / NCI NIH HHS / CA / R01 CA106633-02; United States / NCI NIH HHS / CA / CA106633-03; United States / NCI NIH HHS / CA / R01 CA106633-04; United States / NCI NIH HHS / CA / CA106633-04; United States / NCI NIH HHS / CA / CA106633-01
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pyrazoles; 0 / Sulfonamides; JCX84Q7J1L / Celecoxib; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


23. Manxhuka-Kerliu S, Telaku S, Ahmetaj H, Baruti A, Loxha S, Kerliu A: Colorectal cancer: prognostic values. Bosn J Basic Med Sci; 2009 Feb;9(1):19-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adenocarcinoma was the most frequent histological type found in 85,90% of cases, in 60,94% of males and 39,06% of females; squamous cell carcinoma in 7,38%, in 63,63% of males and 36,36% of females; mucinous carcinoma in 4,68%, in 57,15% of males and 42,85% of females; while adenosquamous carcinoma, undifferentiated carcinoma and carcinoma in situ in 0,71% of cases each.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Squamous Cell / diagnosis. Colorectal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Differentiation. Colon / pathology. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Rectum / pathology. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 1999 Jun;6(4):385-8 [10379860.001]
  • [Cites] Surg Laparosc Endosc. 1998 Aug;8(4):269-72 [9703598.001]
  • [Cites] Am Fam Physician. 2000 Mar 15;61(6):1759-70, 1773-4 [10750881.001]
  • [Cites] Nutr Cancer. 1999;33(1):95-9 [10227050.001]
  • [Cites] Mod Pathol. 2003 Apr;16(4):376-88 [12692203.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):832-9 [15492565.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):527-35 [11159189.001]
  • [Cites] Br J Surg. 1992 Jul;79(7):608-13 [1643467.001]
  • [Cites] Surg Today. 1996;26(9):760-1 [8883258.001]
  • [Cites] Stat Bull Metrop Insur Co. 1999 Jul-Sep;80(3):23-32 [10418079.001]
  • [Cites] Br J Cancer. 2007 Jan 15;96(1):140-2 [17133267.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):673-8 [9708930.001]
  • [Cites] Cancer. 2006 Sep 1;107(5 Suppl):1128-41 [16802325.001]
  • [Cites] Hum Pathol. 1983 Nov;14 (11):931-68 [6629368.001]
  • [Cites] CA Cancer J Clin. 2008 May-Jun;58(3):180-90 [18460593.001]
  • [Cites] World J Gastroenterol. 2007 Jun 7;13(21):3009-15 [17589956.001]
  • [Cites] Lancet Oncol. 2008 Sep;9(9):857-65 [18667357.001]
  • [Cites] Br J Cancer. 1958 Sep;12(3):309-20 [13596482.001]
  • [Cites] Br J Surg. 1985 Sep;72(9):698-702 [4041728.001]
  • [Cites] Pathology. 1993 Jul;25(3):219-22 [8265235.001]
  • (PMID = 19284390.001).
  • [ISSN] 1512-8601
  • [Journal-full-title] Bosnian journal of basic medical sciences
  • [ISO-abbreviation] Bosn J Basic Med Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


24. Kusanagi Y, Kojima A, Mikami Y, Kiyokawa T, Sudo T, Yamaguchi S, Nishimura R: Absence of high-risk human papillomavirus (HPV) detection in endocervical adenocarcinoma with gastric morphology and phenotype. Am J Pathol; 2010 Nov;177(5):2169-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of high-risk human papillomavirus (HPV) detection in endocervical adenocarcinoma with gastric morphology and phenotype.
  • To investigate the HPV-independent pathway of carcinogenesis in cases of gastric-type AC, we investigated the common high-risk HPV (hr-HPV) status in 52 nonsquamous cell carcinomas, using a PCR-based typing method and immunohistochemistry of p16INK4a (a cyclin-dependent kinase inhibitor that is overexpressed in both cancerous and precancerous cervical tissue, making it an ideal biomarker for cervical cancer cases).
  • Using novel morphological criteria, seven of 52 (13.5%) carcinomas were designated as gastric-type ACs, all of which were negative for both hr-HPV DNA and p16INK4a.
  • Nongastric-type ACs were frequently positive for both hr-HPV DNA (90%, 28/31) and p16INK4a (94%, 29/31) with adenosquamous and neuroendocrine carcinomas demonstrating the presence of hr-HPV DNA in 86% (6/7) and 83% (5/6) of cases, respectively.
  • In these two types of carcinoma, 86% (6/7) and 100% (6/6) were positive for p16INK4a, respectively.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / virology. Papillomavirus Infections / pathology. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / virology


25. Fujita T, Fukuda K, Nishi H, Takao T, Ohmura Y, Mano M, Komatsubara S: Paraneoplastic hypercalcemia with adenosquamous carcinoma of the colon. Int J Clin Oncol; 2005 Apr;10(2):144-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraneoplastic hypercalcemia with adenosquamous carcinoma of the colon.
  • Here we present the first case of adenosquamous carcinoma of the sigmoid colon in a patient who was found to have hypercalcemia associated with parathyroid hormone-related protein (PTHrP), with no radiological evidence of metastasis to other organs.
  • The histopathologic diagnosis was poorly differentiated adenosquamous carcinoma.
  • [MeSH-major] Carcinoma, Adenosquamous / complications. Colonic Neoplasms / complications. Hypercalcemia / etiology. Paraneoplastic Syndromes / etiology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15864702.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Parathyroid Hormone-Related Protein
  •  go-up   go-down


26. Lennerz JK, Perry A, Mills JC, Huettner PC, Pfeifer JD: Mucoepidermoid carcinoma of the cervix: another tumor with the t(11;19)-associated CRTC1-MAML2 gene fusion. Am J Surg Pathol; 2009 Jun;33(6):835-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucoepidermoid carcinoma of the cervix: another tumor with the t(11;19)-associated CRTC1-MAML2 gene fusion.
  • Mucoepidermoid carcinoma (MEC) of the uterine cervix is a controversial entity.
  • By strict morphologic criteria, the tumor has features identical to those of salivary gland MEC and is characterized by nests composed of 3 cell types (epidermoid, intermediate, and mucin producing) in the absence of overt glandular differentiation.
  • Given the morphologic similarity between MEC of the cervix and MEC of the salivary glands, we sought to determine if MEC of the cervix harbors the t(11;19)(q21;p13) characteristic of MEC of the major and minor salivary glands, a rearrangement that results in fusion of the cyclic adenosine 3',5' monophosphate coactivator CRTC1 to the Notch coactivator MAML2.
  • We identified 7 cervical tumors from our departmental files and performed reverse transcription-polymerase chain reaction and fluorescence in situ hybridization-based molecular analysis for rearrangements of CRTC1 and MAML2; 14 conventional cervical adenosquamous carcinomas were used as controls.
  • All MEC showed aberrations of at least 1 of the loci, whereas none of the cervical adenosquamous carcinomas harbored rearrangements or amplification of either locus.
  • Our results demonstrate that cervical tumors defined as MEC by strict morphologic criteria harbor genetic aberrations involving the genes characteristically rearranged in MEC of the salivary glands, and suggest that cervical MEC is an entity distinct from conventional cervical adenosquamous carcinoma.
  • The development of drug therapy targeted to the genes rearranged in MEC underscores the importance of correct classification of cervical MEC because the diagnosis may hold therapeutic implications different from other cervical malignancies.

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19092631.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK079798-01A2; United States / NIDDK NIH HHS / DK / K08 DK066062; United States / NIDDK NIH HHS / DK / R01 DK079798; United States / NIDDK NIH HHS / DK / R01 DK079798-01A2; United States / NIDDK NIH HHS / DK / K08 DK066062-05; United States / NIDDK NIH HHS / DK / DK066062-05
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CRTC1 protein, human; 0 / DNA-Binding Proteins; 0 / MAML2 protein, human; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 0 / Transcription Factors
  •  go-up   go-down


27. Bhurgri Y, Nazir K, Shaheen Y, Usman A, Faridi N, Bhurgri H, Malik J, Bashir I, Bhurgri A, Kayani N, Pervez S, Hasan SH, Setna F, Zaidi SM: Patho-epidemiology of Cancer Cervix in Karachi South. Asian Pac J Cancer Prev; 2007 Jul-Sep;8(3):357-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The morphological categorization was squamous cell carcinoma (86.5%), adenocarcinoma (10.9%) and adenosquamous carcinoma (2.6%).
  • Approximately half the cancers (58.1%) had spread regionally and 8.1% to a distant site at the time of diagnosis.
  • CONCLUSION: The incidence of cervical cancer in Karachi South (1995-97) reflects a low risk population with a late presentation and a high stage disease at presentation.


28. Li FQ, Liu Q, Han YL, Wu B, Yin HL: Sperm protein 17 is highly expressed in endometrial and cervical cancers. BMC Cancer; 2010;10:429
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Many studies have examined the role of Sp17 in tumorigenesis and the migration of malignant cells.
  • It has been proposed as a useful target for tumor-vaccine strategies and a novel marker to define tumor subsets and predict drug response.
  • This study aimed to investigate the expression of Sp17 in endometrial and cervical cancer specimens, its possible correlation with the pathological characteristics, and its value in the diagnosis and immunotherapy of the related cancers.
  • METHODS: The monoclonal antibodies against human Sp17 were produced as reagents for the analysis and immunohistochemistry was used to study two major kinds of paraffin-embedded gynecological cancer specimens, including 50 cases of endometrial cancer (44 adenous and 6 adenosquamous) and 31 cases of cervical cancer (15 adenous and 16 squamous).
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, Surface / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / metabolism. Carrier Proteins / metabolism. Endometrial Neoplasms / metabolism. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2007 Apr 15;120(8):1739-47 [17230514.001]
  • [Cites] Lancet. 2003 Jun 28;361(9376):2217-25 [12842378.001]
  • [Cites] J Immunother. 2008 Oct;31(8):693-703 [18779750.001]
  • [Cites] J Transl Med. 2009;7:61 [19604394.001]
  • [Cites] BMC Cancer. 2009;9:323 [19744347.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1508-10 [11222401.001]
  • [Cites] Blood. 2003 Sep 15;102(6):2308-9 [12959941.001]
  • [Cites] Int J Cancer. 2004 Mar 1;108(6):805-11 [14712480.001]
  • [Cites] J Histochem Cytochem. 2004 Apr;52(4):549-54 [15034007.001]
  • [Cites] Br J Dermatol. 2004 Apr;150(4):780-2 [15099386.001]
  • [Cites] Eur J Haematol. 2004 Oct;73(4):280-4 [15347315.001]
  • [Cites] Dev Biol. 1994 Oct;165(2):688-701 [7525387.001]
  • [Cites] Biol Reprod. 1995 Sep;53(3):579-90 [7578682.001]
  • [Cites] Biochim Biophys Acta. 1996 Jul 17;1307(3):263-6 [8688458.001]
  • [Cites] Int Rev Cytol. 1998;177:57-113 [9378618.001]
  • [Cites] Biol Reprod. 1998 Mar;58(3):794-800 [9510968.001]
  • [Cites] J Cell Biochem Suppl. 1997;28-29:90-100 [9589353.001]
  • [Cites] Am J Hematol. 2005 Sep;80(1):6-11 [16138340.001]
  • [Cites] Hum Pathol. 2005 Dec;36(12):1289-93 [16311122.001]
  • [Cites] BMC Cancer. 2006;6:23 [16438728.001]
  • [Cites] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2006 Sep;22(5):638-40 [16948914.001]
  • [Cites] Biochem J. 2001 Jul 1;357(Pt 1):25-31 [11415432.001]
  • [Cites] Eur J Immunol. 2001 Aug;31(8):2277-83 [11477539.001]
  • [Cites] Blood. 2001 Oct 1;98(7):2160-5 [11568003.001]
  • [Cites] J Reprod Med. 2002 Mar;47(3):173-89; discussion 189-90 [11933681.001]
  • [Cites] Cancer. 2002 May 1;94(9):2447-53 [12015770.001]
  • [Cites] Blood. 2002 Aug 1;100(3):961-5 [12130509.001]
  • [Cites] Cancer Lett. 2002 Dec 5;186(2):201-9 [12213290.001]
  • [Cites] Scand J Immunol. 2002 Oct;56(4):429-33 [12234264.001]
  • [Cites] Reproduction. 2002 Dec;124(6):767-74 [12530914.001]
  • [Cites] Dev Immunol. 2002 Jun;9(2):97-102 [12739786.001]
  • [Cites] Int J Gynecol Cancer. 2007 Mar-Apr;17(2):426-32 [17309563.001]
  • (PMID = 20712874.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Immunoglobulin G; 0 / SPA17 protein, human
  • [Other-IDs] NLM/ PMC2931487
  •  go-up   go-down


29. Yin Y, Russell RG, Dettin LE, Bai R, Wei ZL, Kozikowski AP, Kopelovich L, Glazer RI: Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. Cancer Res; 2005 May 1;65(9):3950-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Significantly, tumors from GW7845-treated mice were predominantly ductal adenocarcinomas, whereas tumors from GW501516-treated animals were adenosquamous and squamous cell carcinomas.
  • Only tumors from mice treated with the PPARgamma agonist expressed estrogen receptor-alpha in luminal transit cells, suggesting increased ductal progenitor cell expansion.
  • [MeSH-major] Anticarcinogenic Agents / pharmacology. Carcinoma, Ductal / prevention & control. Mammary Neoplasms, Experimental / prevention & control. Oxazoles / pharmacology. PPAR delta / agonists. PPAR gamma / agonists. Thiazoles / pharmacology. Tyrosine / analogs & derivatives. Tyrosine / pharmacology
  • [MeSH-minor] Animals. Carcinoma, Adenosquamous / chemically induced. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / prevention & control. Carcinoma, Squamous Cell / chemically induced. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / prevention & control. Cell Differentiation / drug effects. Disease Progression. Female. Gene Expression Profiling. Mice

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. L-TYROSINE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer Res. 2005 Jul 1;65(13):5989
  • [ErratumIn] Cancer Res. 2005 Oct 1;65(19):9108. Kopleovich, Levy [corrected to Kopelovich, Levy]
  • (PMID = 15867396.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-25101
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / GW 501516; 0 / GW 7845; 0 / Oxazoles; 0 / PPAR delta; 0 / PPAR gamma; 0 / Thiazoles; 42HK56048U / Tyrosine
  •  go-up   go-down


30. Chen YJ, Tang QB, Zou SQ: Inactivation of RASSF1A, the tumor suppressor gene at 3p21.3 in extrahepatic cholangiocarcinoma. World J Gastroenterol; 2005 Mar 7;11(9):1333-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In all 48 samples and one cell lines of extrahepatic cholangiocarcinoma, the RASSF1A mutation is rare (6.12%, 3/49), 33 samples (68.75%) and QBC-939 cell lines (chi2 = 14.270, P = 0.001 > 0.01) showed RASSF1A express inactivation with LOH at microsatellite loci D3S4604.
  • Among these 33 samples and QBC-939, 28 of 33 (84.85%) tumor samples and 1 cell lines were methylated for majority of 16 CpGs, the average frequency is 73.42%.
  • [MeSH-major] Adenocarcinoma / genetics. Bile Duct Neoplasms / genetics. Bile Ducts, Extrahepatic / pathology. Cholangiocarcinoma / genetics. Chromosomes, Human, Pair 3. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Cell Line, Tumor. CpG Islands / physiology. DNA Methylation. Gene Expression Regulation, Neoplastic. Humans. Loss of Heterozygosity. Neoplasm Staging. Point Mutation. Polymorphism, Single-Stranded Conformational. Promoter Regions, Genetic / physiology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15761971.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC4250680
  •  go-up   go-down


31. Carvalho FM, Zaganelli FL, Almeida BG, Goes JC, Baracat EC, Carvalho JP: Prognostic value of podoplanin expression in intratumoral stroma and neoplastic cells of uterine cervical carcinomas. Clinics (Sao Paulo); 2010;65(12):1279-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of podoplanin expression in intratumoral stroma and neoplastic cells of uterine cervical carcinomas.
  • MATERIALS AND METHODS: A total of 143 patients with clinical stage I and IIA uterine cervical carcinomas underwent surgery between 2000 and 2007.
  • RESULTS: Expression of podoplanin was detected in neoplastic cells in 31/143 (21.6%) cases, with 29/31 (93.5%) of these cases diagnosed as squamous carcinoma.
  • CONCLUSIONS: These preliminary results suggest that podoplanin may have a role in host-tumor interactions and, as a result, may represent a favorable prognostic factor for squamous cervical carcinomas.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Adenosquamous / metabolism. Carcinoma, Adenosquamous / secondary. Membrane Glycoproteins / analysis. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):573-83 [12154350.001]
  • [Cites] Physiol Rev. 2003 Apr;83(2):337-76 [12663862.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):97-104 [15467716.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Cell Biol. 2006 Mar 27;172(7):973-81 [16567498.001]
  • [Cites] Cancer Cell. 2006 Apr;9(4):261-72 [16616332.001]
  • [Cites] Cancer. 2006 Aug 1;107(3):563-9 [16804930.001]
  • [Cites] Br J Cancer. 2007 Jan 15;96(1):1-5 [17179989.001]
  • [Cites] Pathology. 2007 Jun;39(3):305-18 [17558857.001]
  • [Cites] Int J Cancer. 2008 Sep 1;123(5):1053-9 [18546264.001]
  • [Cites] Histol Histopathol. 2009 Aug;24(8):1021-7 [19554509.001]
  • [Cites] Gynecol Oncol. 2009 Aug;114(2):145-50 [19572417.001]
  • [Cites] Oncology. 2009;77(1):53-62 [19556810.001]
  • [Cites] Cancer Causes Control. 2009 Sep;20(7):1129-38 [19253025.001]
  • (PMID = 21340215.001).
  • [ISSN] 1980-5322
  • [Journal-full-title] Clinics (São Paulo, Brazil)
  • [ISO-abbreviation] Clinics (Sao Paulo)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Glycoproteins; 0 / PDPN protein, human
  • [Other-IDs] NLM/ PMC3020337
  •  go-up   go-down


32. Alwaheeb S, Chetty R: Adenosquamous carcinoma of the pancreas with an acantholytic pattern together with osteoclast-like and pleomorphic giant cells. J Clin Pathol; 2005 Sep;58(9):987-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the pancreas with an acantholytic pattern together with osteoclast-like and pleomorphic giant cells.
  • Histological evaluation of the pancreatic tumour showed an adenosquamous carcinoma (predominantly composed of squamous carcinoma), which was extensively infiltrative with perineural invasion and involvement of peripancreatic lymph nodes.
  • Areas of pancreatic intraepithelial neoplasia grade III and merging of the squamous and adenocarcinoma components were evident.
  • Unusual histological features that characterised this case included a pronounced acantholytic pattern within the squamous carcinoma component, and the presence of both osteoclastic and pleomorphic giant cells.
  • Giant cells have not been documented previously in association with an adenosquamous carcinoma.
  • Although an acantholytic pattern has been noted in squamous carcinomas in other sites, this is the first report of such a pattern in an adenosquamous carcinoma of the pancreas.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Giant Cells / pathology. Osteoclasts / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2000 Oct;31(10):1223-9 [11070115.001]
  • [Cites] Mod Pathol. 2001 May;14(5):443-51 [11353055.001]
  • [Cites] JOP. 2004 Jul;5(4):220-4 [15254351.001]
  • [Cites] Cancer. 1972 May;29(5):1133-40 [5021607.001]
  • [Cites] J Surg Oncol. 1973;5(4):335-58 [4355621.001]
  • [Cites] J Surg Oncol. 1980;14(3):261-5 [7392648.001]
  • [Cites] Gastroenterology. 1982 Dec;83(6):1297-9 [7129033.001]
  • [Cites] Acta Cytol. 1984 Nov-Dec;28(6):733-6 [6594886.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1988;412(3):247-53 [3124345.001]
  • [Cites] Gan No Rinsho. 1990 May;36(6):728-32 [2348561.001]
  • [Cites] Hum Pathol. 1991 Jun;22(6):618-22 [1864595.001]
  • [Cites] Hum Pathol. 1992 Jun;23(6):703-6 [1592394.001]
  • [Cites] Pancreas. 1992;7(5):611-5 [1513808.001]
  • [Cites] Pathology. 1993 Oct;25(4):420-2 [8165013.001]
  • [Cites] Int J Pancreatol. 1995 Oct;18(2):169-75 [8530833.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1279-87 [9529019.001]
  • [Cites] Pathol Res Pract. 1998;194(8):587-94; discussion 595 [9779494.001]
  • [Cites] Arch Surg. 1999 Jun;134(6):599-603 [10367867.001]
  • [Cites] AMA Arch Pathol. 1954 Aug;58(2):101-11 [13170907.001]
  • [Cites] Int J Pancreatol. 1999 Oct;26(2):85-91 [10597404.001]
  • [Cites] Pathol Int. 2000 Jul;50(7):562-7 [10886741.001]
  • (PMID = 16126885.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1770836
  •  go-up   go-down


33. Baker AC, Eltoum I, Curry RO, Stockard CR, Manne U, Grizzle WE, Chhieng D: Mucinous expression in benign and neoplastic glandular lesions of the uterine cervix. Arch Pathol Lab Med; 2006 Oct;130(10):1510-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous expression in benign and neoplastic glandular lesions of the uterine cervix.
  • CONTEXT: Mucins are glycoproteins produced by both normal and neoplastic glandular epithelial cells including endocervix.
  • OBJECTIVE: To determine the expression of mucins in uterine cervical glandular lesions and whether mucin expression correlates with the nature and origin of the glandular lesions.
  • DESIGN: Antibodies to MUC1, MUC2, MUC4, and MUC5AC were applied on 52 cases including 14 endocervical adenocarcinomas (including 4 adenosquamous carcinomas), 9 endometrial carcinomas (8 endometrioid adenocarcinomas and 1 adenosquamous carcinoma), 8 adenocarcinoma in situ (AIS), 2 glandular dysplasias, 6 tubal metaplasias, 10 microglandular hyperplasias, and 3 normal endocervix.
  • Almost all endocervical AIS and carcinomas and all endometrial adenocarcinomas expressed MUC1; the exceptions were 2 cases of endocervical adenocarcinoma and 1 case of adenosquamous carcinoma of the endocervix.
  • These results suggest that mucin staining may potentially be helpful in differentiating various uterine cervical glandular lesions.
  • [MeSH-major] Adenocarcinoma / metabolism. Mucins / metabolism. Uterine Cervical Diseases / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Carcinoma / metabolism. Endometrial Neoplasms / metabolism. Female. Humans. Immunohistochemistry / methods. Mucin 5AC. Mucin-1 / metabolism. Mucin-2. Mucin-4. Staining and Labeling

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Cervix Disorders.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17090193.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MUC2 protein, human; 0 / MUC4 protein, human; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-1; 0 / Mucin-2; 0 / Mucin-4; 0 / Mucins
  •  go-up   go-down


34. Vrdoljak E, Omrcen T, Novaković ZS, Jelavić TB, Prskalo T, Hrepić D, Hamm W: Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy for women with locally advanced carcinoma of the uterine cervix--final results of a prospective phase II-study. Gynecol Oncol; 2006 Nov;103(2):494-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy for women with locally advanced carcinoma of the uterine cervix--final results of a prospective phase II-study.
  • OBJECTIVES: To evaluate the efficacy and toxicity of ifosfamide and cisplatin administered concomitantly with low-dose rate brachyradiotherapy followed by consolidation chemotherapy in the treatment of locally advanced squamous cell carcinoma (LASCC) or adeno/adenosquamous carcinoma of the uterine cervix.
  • The patients had to have FIGO-stage IB2 bulky to IVA disease, biopsy-proven squamous cell or adeno/adenosquamous carcinoma of the uterine cervix.
  • CONCLUSION: These results indicate that concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy with the same drug combination is a highly efficacious and very promising treatment protocol for patients with locally advanced LASCC or adeno/adenosquamous carcinoma of the uterine cervix.
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Disease-Free Survival. Dose Fractionation. Drug Administration Schedule. Female. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Middle Aged. Neoplasm Staging. Prospective Studies


35. Tiltman AJ: The pathology of cervical tumours. Best Pract Res Clin Obstet Gynaecol; 2005 Aug;19(4):485-500
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carcinomas of the cervix may be categorized on morphological grounds into four main groups: squamous carcinomas; adenocarcinomas; neuro-endocrine tumours; and others including adenosquamous carcinomas.
  • Invasive squamous carcinomas and adenocarcinomas are preceded by cervical intra-epithelial neoplasia and cervical glandular intra-epithelial neoplasia, respectively.
  • Micro-invasive carcinomas with stromal invasion less than 3mm in depth have a minimal chance of lymph node metastasis.
  • Small cell carcinomas, large cell neuro-endocrine carcinomas and possibly adenoid cystic carcinomas are aggressive.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Neuroendocrine Tumors / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16150389.001).
  • [ISSN] 1521-6934
  • [Journal-full-title] Best practice & research. Clinical obstetrics & gynaecology
  • [ISO-abbreviation] Best Pract Res Clin Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  • [Number-of-references] 94
  •  go-up   go-down


36. Calkins A, Stehman FB, Bundy B, Benda JA, Mannel RS, Seago P, Cappuccini F, Alvarez RD, Monk BJ, Maiman M: Human immunodeficiency virus testing in patients with invasive cervical carcinoma: a prospective trial of the gynecologic oncology group. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):660-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human immunodeficiency virus testing in patients with invasive cervical carcinoma: a prospective trial of the gynecologic oncology group.
  • [MeSH-major] HIV Infections / diagnosis. Uterine Cervical Neoplasms / virology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / virology. Adult. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / virology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / virology. Enzyme-Linked Immunosorbent Assay. Female. HIV-1 / isolation & purification. Humans. Middle Aged. Neoplasm Invasiveness. Prognosis. Prospective Studies


37. Sun Y, Lin H, Zhu Y, Feng J, Chen Z, Li G, Zhang X, Zhang Z, Tang J, Shi M, Hao X, Han H: [A randomized, prospective, multi-centre clinical trial of NP regimen (vinorelbine+cisplatin) plus Gensing Rg3 in the treatment of advanced non-small cell lung cancer patients]. Zhongguo Fei Ai Za Zhi; 2006 Jun 20;9(3):254-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A randomized, prospective, multi-centre clinical trial of NP regimen (vinorelbine+cisplatin) plus Gensing Rg3 in the treatment of advanced non-small cell lung cancer patients].
  • The aim of this study is to observe the clinical anticancer effect of Rg3 in combination with chemotherapy regimen NP (vinorelbine+cisplatin) in advanced non-small cell lung cancer (NSCLC).
  • Types of pathology: adenocarcinoma, 71; squamous cell carcinoma, 29; adenosquamous carcinoma, 8; others, 7.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21172156.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


38. Gatlez J, Hendlisz A, Legendre H, Sirtaine N, Debroux S, Awada A: [Colorectal epidermoid carcinoma and paraneoplastic hypercalcemia]. Acta Clin Belg; 2007 Nov-Dec;62(6):433-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Colorectal epidermoid carcinoma and paraneoplastic hypercalcemia].
  • [Transliterated title] Carcinome épidermoïde colorectal et hypercalcémie paranéoplasique.
  • The squamous cell carcinoma and the adenosquamous cell carcinoma of the colon and rectum are not well know and rare tumours.
  • We report a case of squamous cell carcinoma of the recto-sigmoid who relapses in the liver after surgery of the primary tumour with paraneoplasic hypercalcaemia.
  • We will discuss the pathogenesis, prognosis, associated conditions, clinical features and treatment strategies of squamous and adenosquamous cell carcinoma of the colon and the rectum.
  • [MeSH-major] Carcinoma, Adenosquamous / secondary. Hypercalcemia / etiology. Paraneoplastic Syndromes / etiology. Sigmoid Neoplasms / pathology

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18351188.001).
  • [ISSN] 1784-3286
  • [Journal-full-title] Acta clinica Belgica
  • [ISO-abbreviation] Acta Clin Belg
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


39. Xu ML, Liu Y, Zhong HH, Wu BQ: [Status and clinicopathologic implication of epidermal growth factor receptor mutation in non-small cell carcinoma of lung]. Zhonghua Bing Li Xue Za Zhi; 2007 Jul;36(7):453-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Status and clinicopathologic implication of epidermal growth factor receptor mutation in non-small cell carcinoma of lung].
  • OBJECTIVE: To investigate mutations of epidermal growth factor receptor (EGFR) exon 19 and 21 in non-small cell lung carcinoma and to explore their clinicopathological correlations.
  • METHOD: DNA was extracted from the excised tumor specimens of 66 non-small cell lung carcinoma patients by traditional phenol-chloroform and ethanol precipitation.
  • Mutations were more frequently observed in women (9/34, 26.5%) than in men (2/32, 6.3%), in adenocarcinomas (10/43, 23.3%) than squamous (0/13) and adenosquamous carcinomas (1/10).
  • Those with adenocarcinoma with bronchiolo-alveolar carcinoma (BAC) components had higher frequency of EGFR mutation (6/11) than those without non-BAC element (4/32, 12.5%).
  • [MeSH-major] Amino Acid Substitution. Carcinoma, Non-Small-Cell Lung / genetics. Gene Deletion. Lung Neoplasms / genetics. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adult. Aged. DNA Mutational Analysis. DNA, Neoplasm / genetics. Exons. Female. Humans. Male. Middle Aged. Mutation. Sex Factors

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17845757.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


40. Frumovitz M, Sun CC, Schover LR, Munsell MF, Jhingran A, Wharton JT, Eifel P, Bevers TB, Levenback CF, Gershenson DM, Bodurka DC: Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol; 2005 Oct 20;23(30):7428-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eligible women had squamous cell tumors smaller than 6 cm at diagnosis, were currently disease-free, and had either undergone surgery or radiotherapy, but not both.
  • [MeSH-minor] Adenocarcinoma / psychology. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Adult. Carcinoma, Adenosquamous / psychology. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / psychology. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Case-Control Studies. Female. Humans. Hysterectomy. Middle Aged. Surveys and Questionnaires


41. Wang MQ, Zhang QH, Guo LL, Cai YR, Wang Y: [Pathologic diagnosis of endometrial carcinoma in curettage specimens in women under forty years of age]. Zhonghua Bing Li Xue Za Zhi; 2005 May;34(5):262-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pathologic diagnosis of endometrial carcinoma in curettage specimens in women under forty years of age].
  • OBJECTIVE: To investigate the diagnostic pathological features of endometrial carcinomas present in women under 40 years of age (by curettage samples).
  • METHODS: A retrospective analysis was performed on 20 cases of endometrial carcinomas in women under 40 years of age.
  • RESULTS: The patients included 18 endometrioid adenocarcinoma cases, one adenosquamous carcinoma case, and one papillary serous carcinoma case.
  • The adenosquamous case metastasized to the ovaries and the papillary serous carcinoma case metastasized to the pelvic lymph nodes.
  • CONCLUSIONS: Endometrial carcinomas which are highly differentiated endometrioid adenocarcinomas occur frequently in women under 40 years of age.
  • An important differential diagnosis of the endometrioid carcinoma in a curettage specimen is to differentiate it from atypical endometrial hyperplasia and atypical polypoid adenomyoma.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology
  • [MeSH-minor] Adenomyoma / pathology. Adult. Carcinoma, Adenosquamous / secondary. Carcinoma, Papillary / pathology. Diagnosis, Differential. Dilatation and Curettage. Endometrial Hyperplasia / pathology. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Myometrium / pathology. Ovarian Neoplasms / secondary. Pelvis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16181545.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


42. Chiarion-Sileni V, Innocente R, Cavina R, Ruol A, Corti L, Pigozzo J, Del Bianco P, Fumagalli U, Santoro A, Ancona E: Multi-center phase II trial of chemo-radiotherapy with 5-fluorouracil, leucovorin and oxaliplatin in locally advanced esophageal cancer. Cancer Chemother Pharmacol; 2009 May;63(6):1111-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Fifty-nine patients with adeno or squamous-cell carcinoma received oxaliplatin (60 mg/m(2)), and leucovorin (20 mg/m(2) on days 1,8,15,29,36,43,50,57) followed by continuous infusion fluorouracil (200 mg/m(2) per day on days 1-22 and 29-64) with radiotherapy (1.8 Gy daily fractions to a total dose of 45 Gy, from days 29 to 64).
  • Esophagectomy was possible in 33 patients and a complete resection (R0) was achieved in 26 (79%) with 6 pathologic complete responses (pCR) and 3 near pCR.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Drug Administration Schedule. Esophagectomy. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / therapeutic use. Humans. Kaplan-Meier Estimate. Leucovorin / administration & dosage. Leucovorin / adverse effects. Leucovorin / therapeutic use. Male. Middle Aged. Neoplasm Invasiveness. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / adverse effects. Organoplatinum Compounds / therapeutic use. Radiation Dosage

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18825381.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


43. Shin JU, Jung JT, You SS, Kwon JG, Kim EY, Lee CH, Kim HG, Park JB: [A case of primary adenosquamous carcinoma of the liver with formation of colonic fistula]. Korean J Gastroenterol; 2006 Nov;48(5):360-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary adenosquamous carcinoma of the liver with formation of colonic fistula].
  • Primary adenosquamous carcinoma of the liver is generally considered as an extremely rare subtype of cholangiocarcinoma.
  • Recently, we experienced a case of primary adenosquamous carcinoma of liver with a formation of tumor-colonic fistula.
  • Colonoscopic examination showed a large colonic wall defect in hepatic flexure and a friable, nodular mucosa around the defected colonic wall.
  • Microscopically, the tumor was composed of squamous cell carcinoma mainly with foci of the adenocarcinoma component.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Colonic Diseases / pathology. Intestinal Fistula / pathology. Liver Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17132926.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


44. Sasieni P, Castanon A, Cuzick J: Screening and adenocarcinoma of the cervix. Int J Cancer; 2009 Aug 1;125(3):525-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening and adenocarcinoma of the cervix.
  • Although there can be no doubt about its effectiveness in preventing squamous-cell carcinoma, there is little evidence of any benefit on adenocarcinoma and adenosquamous carcinoma of the cervix, and many authors have concluded that it is ineffective.
  • Among 3,305 cases with known histology, 641 had adenocarcinoma and 133 adenosquamous carcinoma.
  • The risk reduction associated with 3-yearly screening was greater for squamous carcinoma (75%, 95%CI 71-79%) and adenosquamous carcinoma (83%, 95%CI 68-91%) than for adenocarcinoma (43%, 95%CI 24-58%).
  • Among stage 1B+ cases, 83% (335/406) of women with adenocarcinoma had been screened within 10 years of diagnosis.
  • This is very similar to controls (82%, 3,292/3,965), but much higher than in women with squamous carcinoma (57%, 852/1,493).
  • Incidence of adenocarcinoma was low within 2.5 years of a negative smear (OR 2.3, 95%CI 0.15-0.34), but was no different from the background rates 4.5-5.5 years after a negative smear.
  • We conclude that screening has reduced the incidence of adenocarcinoma of the cervix, but the prognostic value of cytology is less (in both magnitude and duration) for adenocarcinoma than for squamous carcinoma.
  • The impact of screening on adenosquamous carcinoma is similar to its impact on squamous carcinoma.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / prevention & control. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Adenosquamous / prevention & control. Mass Screening. Uterine Cervical Neoplasms / epidemiology. Uterine Cervical Neoplasms / prevention & control
  • [MeSH-minor] Adult. Aged. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / prevention & control. Case-Control Studies. Colposcopy. Female. Great Britain / epidemiology. Humans. Incidence. Logistic Models. Middle Aged. Neoplasm Invasiveness


45. Milam MR, Abaid L, dos Reis R, Frumovitz M, Gehrig PA, Livasy C, Broaddus RR, Ramirez PT: Microscopic evaluation of lymph-node-bearing tissue in early-stage cervical cancer: a dual-institution review. Ann Surg Oncol; 2010 Apr;17(4):1106-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Adenosquamous / secondary. Carcinoma, Squamous Cell / secondary. Lymph Nodes / pathology. Uterine Cervical Neoplasms / pathology


46. Zhao S, Shao K, Ye B, Liu X, Cheng G, Sun K, Meng P, He J: [Prognostic factors for survival after lung cancer surgery in elderly patients]. Zhongguo Fei Ai Za Zhi; 2007 Oct 20;10(5):391-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor characteristics: squamous cell carcinoma 49.0%, adenocarcinoma 35.9%, adenosquamous carcinoma 8.3%, small cell lung cancer 4.7%, others 2.1%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21126407.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


47. Hong SM, Cho H, Moskaluk CA, Frierson HF Jr, Yu E, Ro JY: CDX2 and MUC2 protein expression in extrahepatic bile duct carcinoma. Am J Clin Pathol; 2005 Sep;124(3):361-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CDX2 and MUC2 protein expression in extrahepatic bile duct carcinoma.
  • Although CDX2-mediated intestinal metaplasia and its association with gastric and esophageal carcinoma have been well described, its function in extrahepatic bile duct (EBD) carcinoma remains unclear.
  • CDX2 and MUC2 expression were examined in 193 EBD carcinomas, and observed in 37.3% and 42.0%, respectively.
  • Both CDX2 and MUC2 were observed in 27.4%. CDX2 (P<.001) and MUC2 (P<.001) were correlated with histologic subtypes and present, respectively, in all intestinal-type adenocarcinomas and mucinous carcinomas, 12 (71%) and 13 (76%) of 17 papillary carcinomas, 2 (40%) and 2 (40%) of 5 adenosquamous carcinomas, and 28.4% and 33.5% of adenocarcinomas, not otherwise specified.
  • Expression of CDX2 and MUC2 supports that intestinal differentiation is present in specific subtypes of EBD carcinomas, and their expression status correlates with patients' overall survival.

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16191504.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / MUC2 protein, human; 0 / Mucin-2; 0 / Mucins
  •  go-up   go-down


48. Rotman M, Sedlis A, Piedmonte MR, Bundy B, Lentz SS, Muderspach LI, Zaino RJ: A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys; 2006 May 1;65(1):169-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study.
  • The RT arm showed a statistically significant (46%) reduction in risk of recurrence (hazard ratio [HR] = 0.54, 90% confidence interval [CI] = 0.35 to 0.81, p = 0.007) and a statistically significant reduction in risk of progression or death (HR = 0.58, 90% CI = 0.40 to 0.85, p = 0.009).
  • With RT, 8.8% of patients (3 of 34) with adenosquamous or adenocarcinoma tumors recurred vs. 44.0% (11 of 25) in OBS.
  • Fewer recurrences were seen with RT in patients with adenocarcinoma or adenosquamous histologies relative to others (HR for RT by histology interaction = 0.23, 90% CI = 0.07 to 0.74, p = 0.019).
  • RT appears to be particularly beneficial for patients with adenocarcinoma or adenosquamous histologies.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Female. Humans. Hysterectomy. Lymph Node Excision. Pelvis. Radiotherapy Dosage. Survival Analysis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16427212.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


49. Radaelli E, Arnold A, Papanikolaou A, Garcia-Fernandez RA, Mattiello S, Scanziani E, Cardiff RD: Mammary tumor phenotypes in wild-type aging female FVB/N mice with pituitary prolactinomas. Vet Pathol; 2009 Jul;46(4):736-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prolactin-secreting pituitary proliferations play a significant role in mouse mammary tumorigenesis generally producing adenosquamous carcinomas.
  • Compared with previous reports, prolactinoma-associated mammary tumors displayed a broader morphologic spectrum, including cases with the EMT phenotype.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19276050.001).
  • [ISSN] 1544-2217
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA141582; United States / NCI NIH HHS / CA / CA55909
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


50. Kiran RP, Tripodi G, Frederick W, Dudrick SJ: Adenosquamous carcinoma of the colon: a rare tumor. Am Surg; 2006 Aug;72(8):754-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the colon: a rare tumor.
  • Adenosquamous carcinoma of the colon is rare.
  • Survival for more advanced stages of disease is lower than for patients with adenocarcinoma at a corresponding stage.
  • We report a patient who presented with a primary adenosquamous carcinoma of the rectosigmoid junction and we review the literature regarding the clinical presentation, management, and prognosis of this tumor.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Colectomy / methods. Colonic Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Biopsy. Diagnosis, Differential. Follow-Up Studies. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16913323.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Li J, Zhang DC, He J, Liu XY, Mu JW, Zhang LZ: [The rule of lymph node metastasis of adenosquamous carcinoma of the lung]. Zhonghua Zhong Liu Za Zhi; 2009 Jul;31(7):524-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The rule of lymph node metastasis of adenosquamous carcinoma of the lung].
  • OBJECTIVE: To investigate the rule of lymph node metastasis of adenosquamous carcinoma of the lung.
  • METHODS: The data of 361 surgically treated patients with adenosquamous carcinoma of the lung from October 1965 to June 2003 were collected and retrospectively reviewed.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Lung Neoplasms / pathology. Lymph Nodes / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19950701.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


52. Ueda Y, Miyatake T, Okazawa M, Kimura T, Miyake T, Fujiwara K, Yoshino K, Nakashima R, Fujita M, Enomoto T: Clonality and HPV infection analysis of concurrent glandular and squamous lesions and adenosquamous carcinomas of the uterine cervix. Am J Clin Pathol; 2008 Sep;130(3):389-400
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonality and HPV infection analysis of concurrent glandular and squamous lesions and adenosquamous carcinomas of the uterine cervix.
  • We analyzed the clonality and human papillomavirus (HPV) infection status of concurrent glandular and squamous lesions and adenosquamous carcinomas of the uterine cervix to clarify their histogenesis.
  • The glandular and squamous components were clonally different from each other in 7 informative concurrent lesions.
  • HPV was episomal in 2 polyclonal glandular dysplasias (GDs).
  • HPV was in a mixed integrated-episomal form in a monoclonal GD, an adenocarcinoma in situ, and an adenocarcinoma.
  • Both tumor components were monoclonal in origin in 6 adenosquamous carcinomas, with identical patterns of X-chromosomal inactivation and types and physical status of HPV.
  • These results imply that the concurrent glandular and squamous lesions are formed separately, whereas adenosquamous carcinoma is more likely to be a combination tumor of monoclonal origin, and that integration of HPV has an important role in the progression from polyclonal GD through monoclonal expansion to adenocarcinoma in situ and adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / virology. Carcinoma, Adenosquamous / virology. Carcinoma, Squamous Cell / virology. Cervix Uteri / pathology. Cervix Uteri / virology. Endometrial Neoplasms / virology. Papillomavirus Infections / pathology

  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18701412.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral
  •  go-up   go-down


53. Shutoh M, Oue N, Aung PP, Noguchi T, Kuraoka K, Nakayama H, Kawahara K, Yasui W: DNA methylation of genes linked with retinoid signaling in gastric carcinoma: expression of the retinoid acid receptor beta, cellular retinol-binding protein 1, and tazarotene-induced gene 1 genes is associated with DNA methylation. Cancer; 2005 Oct 15;104(8):1609-19
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA methylation of genes linked with retinoid signaling in gastric carcinoma: expression of the retinoid acid receptor beta, cellular retinol-binding protein 1, and tazarotene-induced gene 1 genes is associated with DNA methylation.
  • To the authors' knowledge, little is known regarding the involvement of these three genes in gastric carcinoma (GC).
  • METHODS: DNA methylation of 3 retinoic acid-associated genes was analyzed in 42 samples of GC from 42 patients and in 8 GC cell lines by methylation-specific polymerase chain reaction (PCR) analysis.
  • RESULTS: In 7 of 8 GC cell lines, the CRBP1 gene was hypermethylated, and CRBP1 transcription was inactive.
  • In 6 of 8 GC cell lines, the TIG1 gene was hypermethylated, and TIG1 transcription was inactive.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Azacitidine / pharmacology. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / pathology. Female. Gastric Mucosa / metabolism. Gastric Mucosa / pathology. Gene Silencing. Genes, Tumor Suppressor. Humans. Intestinal Neoplasms / genetics. Intestinal Neoplasms / pathology. Male. Metaplasia / genetics. Metaplasia / pathology. Middle Aged. Promoter Regions, Genetic / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Retinol-Binding Proteins, Cellular. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction. Transcription, Genetic. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society
  • (PMID = 16134180.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / RARRES1 protein, human; 0 / RBP1 protein, human; 0 / RNA, Messenger; 0 / Receptors, Retinoic Acid; 0 / Retinoids; 0 / Retinol-Binding Proteins; 0 / Retinol-Binding Proteins, Cellular; 0 / retinoic acid receptor beta; M801H13NRU / Azacitidine
  •  go-up   go-down


54. Wydra D, Sawicki S, Wojtylak S, Bandurski T, Emerich J: Sentinel node identification in cervical cancer patients undergoing transperitoneal radical hysterectomy: a study of 100 cases. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):649-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Carcinoma, Adenosquamous / radionuclide imaging. Carcinoma, Squamous Cell / radionuclide imaging. Hysterectomy. Peritoneum / surgery. Uterine Cervical Neoplasms / radionuclide imaging


55. Mori T, Nomori H, Ikeda K, Kawanaka K, Shiraishi S, Katahira K, Yamashita Y: Diffusion-weighted magnetic resonance imaging for diagnosing malignant pulmonary nodules/masses: comparison with positron emission tomography. J Thorac Oncol; 2008 Apr;3(4):358-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion-weighted magnetic resonance imaging for diagnosing malignant pulmonary nodules/masses: comparison with positron emission tomography.
  • INTRODUCTION: Recent developments of diffusion-weighted magnetic resonance imaging (DWI) make it possible to image malignant tumors to provide tissue contrast based on difference in the diffusion of water molecules among tissues, which can be measured by apparent diffusion coefficient (ADC) value.
  • The aim of this study is to examine the usefulness of DWI for benign/malignant discrimination of pulmonary nodules/masses compared with F-fluorodeoxyglucose (FDG) positron emission tomography (PET).
  • RESULTS: The receiver operating characteristics curve showed cutoff values of the ADC-min and the SUV-CR for benign/malignant discrimination to be 1.1 x 10 mm/s and 0.37, respectively.
  • CONCLUSIONS: DWI may be able to be used in place of FDG-PET to distinguish malignant from benign pulmonary nodules/masses with fewer false-positive results compared with FDG-PET.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging / methods. Lung Neoplasms / diagnosis. Positron-Emission Tomography / methods. Solitary Pulmonary Nodule / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / diagnosis. Carcinoma, Squamous Cell / diagnosis. Diagnostic Imaging. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Prognosis. Prospective Studies. ROC Curve. Sensitivity and Specificity. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379353.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


56. Zainuddin MA, Hong TY: Primary renal adenosquamous carcinoma. Urol Ann; 2010 Sep;2(3):122-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary renal adenosquamous carcinoma.
  • A case of renal adenosquamous carcinoma is presented.
  • The fact that the urothelium has no glandular or squamous structures makes the pathogenesis of this tumor unique.
  • The process is assumed to begin with urothelial metaplasia resulting from chronic irritation leading to dysplasia and subsequently squamous and glandular differentiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20981201.001).
  • [ISSN] 0974-7834
  • [Journal-full-title] Urology annals
  • [ISO-abbreviation] Urol Ann
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2955228
  • [Keywords] NOTNLM ; Adenosquamous carcinoma / metaplasia / renal
  •  go-up   go-down


57. Lada PE, Taborda B, Sánchez M, Tommasino J, Rosso FF, Gramática L, Alecha Gil J, Echenique Elizondo M: [Adenosquamous and squamous carcinoma of the gallbladder]. Cir Esp; 2007 Apr;81(4):202-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenosquamous and squamous carcinoma of the gallbladder].
  • [Transliterated title] Carcinoma adenoescamoso y epidermoide de la vesícula biliar.
  • INTRODUCTION: Squamous and adenosquamous carcinomas of the gallbladder have poor prognosis.
  • MATERIAL AND METHOD: We performed a retrospective observational study of five patients with squamous or adenosquamous carcinoma of the gallbladder.
  • None of the patients had jaundice and all had gallstone disease.
  • Pathologic analysis revealed epidermoid carcinoma in two patients and adenosquamous carcinoma in three patients.
  • CONCLUSIONS: In both histological types of gallbladder carcinoma, treatment depends on the grade of local and regional invasion and tumor spread at diagnosis.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Gallbladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17403356.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


58. Fitzgerald TL, Hickner ZJ, Schmitz M, Kort EJ: Changing incidence of pancreatic neoplasms: a 16-year review of statewide tumor registry. Pancreas; 2008 Aug;37(2):134-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Although most pancreatic neoplasms are adenocarcinoma, there are many other histological types, some of which may be increasing in frequency.
  • The most common were adenocarcinoma, mucinous cystadenocarcinoma, nonfunctional neuroendocrine, adenosquamous, anaplastic, intraductal papillary mucinous, and acinar cell (8.37, 0.43, 0.18, 0.05, 0.04, 0.04, and 0.02 per 100,000 per year, respectively).
  • [MeSH-minor] Adenocarcinoma / epidemiology. Aged. Carcinoma, Acinar Cell / epidemiology. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Pancreatic Ductal / epidemiology. Cystadenocarcinoma, Mucinous / epidemiology. Female. Humans. Male. Michigan / epidemiology. Middle Aged. Neuroendocrine Tumors / epidemiology. Registries. Time Factors

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18665072.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Pearl ML, Johnston CM, McMeekin DS: A phase II study of weekly docetaxel for patients with advanced or recurrent cancer of the cervix. Gynecol Obstet Invest; 2007;64(4):193-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Eligible patients were required to have measurable disease with adequate performance status, bone marrow, renal and hepatic function.
  • Docetaxel 35 mg/m2 was administered intravenously weekly for 3 weeks followed by 1 week off until disease progression or adverse effects prohibited further therapy.
  • Three patients had stable disease up to 6 cycles.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adult. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Middle Aged. Oklahoma. Survival Analysis. Treatment Outcome


60. Delpech Y, Haie-Meder C, Rey A, Zafrani Y, Uzan C, Gouy S, Pautier P, Lhommé C, Duvillard P, Castaigne D, Morice P: Para-aortic involvement and interest of para-aortic lymphadenectomy after chemoradiation therapy in patients with stage IB2 and II cervical carcinoma radiologically confined to the pelvic cavity. Ann Surg Oncol; 2007 Nov;14(11):3223-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Para-aortic involvement and interest of para-aortic lymphadenectomy after chemoradiation therapy in patients with stage IB2 and II cervical carcinoma radiologically confined to the pelvic cavity.
  • BACKGROUND: Pelvic radiation therapy with concomitant chemotherapy (PCRT) is the standard treatment of stage IB2/II cervical carcinoma.
  • (1) stage IB2/II cervical carcinoma, (2) histological subtype: squamous cell, adenocarcinoma or an adenosquamous tumor, (3) exclusion of patients with radiological PA+ (CT scan/MRI), (4) pelvic external radiation therapy of 45 Gy with concomitant chemotherapy (cisplatin 40 mg/m2/week) + utero-vaginal brachytherapy, and (5) completion surgery after the end of PCRT including at least a para-aortic lymphadenectomy.
  • Overall and disease-free survival at 24 months in patients with PA+ was 40% and 17%.
  • CONCLUSIONS: The rate of PA+ remains high after PCRT in patients treated for stage IB2/II cervical carcinoma.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Adult. Aged. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy. Disease-Free Survival. Female. France / epidemiology. Humans. Laparoscopy. Lymphatic Metastasis. Middle Aged. Predictive Value of Tests. Retrospective Studies. Survival Rate


61. McDermott U, Ames RY, Iafrate AJ, Maheswaran S, Stubbs H, Greninger P, McCutcheon K, Milano R, Tam A, Lee DY, Lucien L, Brannigan BW, Ulkus LE, Ma XJ, Erlander MG, Haber DA, Sharma SV, Settleman J: Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. Cancer Res; 2009 May 1;69(9):3937-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using a high-throughput cancer cell line screening platform, we found that only 2 of 637 tested human tumor-derived cell lines show significant sensitivity to single-agent sunitinib exposure.
  • These two cell lines [a non-small-cell lung cancer (NSCLC) and a rhabdomyosarcoma] showed expression of highly phosphorylated PDGFRA.
  • In the sunitinib-sensitive adenosquamous NSCLC cell line, PDGFRA expression was associated with focal PFGRA gene amplification, which was similarly detected in a small fraction of squamous cell NSCLC primary tumor specimens.
  • Moreover, in this NSCLC cell line, focal amplification of the gene encoding the PDGFR ligand PDGFC was also detected, and silencing PDGFRA or PDGFC expression by RNA interference inhibited proliferation.
  • A similar codependency on PDGFRA and PDGFC was observed in the sunitinib-sensitive rhabdomyosarcoma cell line.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2008 May 15;112(10):2119-29 [18338812.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3389-95 [18451166.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2442-9 [18458038.001]
  • [Cites] Mod Pathol. 2000 Jun;13(6):632-7 [10874667.001]
  • [Cites] Oncogene. 2000 Dec 11;19(53):6093-101 [11156522.001]
  • [Cites] Oncogene. 2001 Feb 1;20(5):626-33 [11313995.001]
  • [Cites] Nat Genet. 2001 Oct;29(2):143-52 [11544480.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):327-37 [12538485.001]
  • [Cites] Science. 2003 Jan 31;299(5607):708-10 [12522257.001]
  • [Cites] N Engl J Med. 2003 Mar 27;348(13):1201-14 [12660384.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4342-9 [14645423.001]
  • [Cites] Bioinformatics. 2004 May 22;20(8):1233-40 [14871870.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Cell. 1984 Nov;39(1):89-97 [6091919.001]
  • [Cites] Cell. 1986 Jul 18;46(2):155-69 [3013421.001]
  • [Cites] Cell. 1993 Apr 23;73(2):321-34 [7682895.001]
  • [Cites] Int J Cancer. 1995 Jan 17;60(2):168-73 [7829210.001]
  • [Cites] J Clin Oncol. 2005 Aug 10;23(23):5357-64 [15928335.001]
  • [Cites] Nat Biotechnol. 2005 Sep;23(9):1147-57 [16151408.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2316-21 [16461907.001]
  • [Cites] Lancet. 2006 Oct 14;368(9544):1329-38 [17046465.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] Gynecol Oncol. 2007 Mar;104(3):524-8 [17049587.001]
  • [Cites] Nature. 2007 Aug 2;448(7153):561-6 [17625570.001]
  • [Cites] Pediatr Blood Cancer. 2008 Feb;50(2):254-8 [17262795.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19936-41 [18077425.001]
  • [Cites] Cell. 2007 Dec 14;131(6):1190-203 [18083107.001]
  • [Cites] Hum Pathol. 2008 Feb;39(2):184-93 [17950782.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):650-6 [18235126.001]
  • [Cites] Genes Dev. 2008 May 15;22(10):1276-312 [18483217.001]
  • (PMID = 19366796.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P20 CA090578; United States / NCI NIH HHS / CA / P50 CA090578-060008; United States / NCI NIH HHS / CA / CA115830-04; United States / NCI NIH HHS / CA / P20 CA090578-06; United States / NCI NIH HHS / CA / R01 CA115830-04; United States / NCI NIH HHS / CA / CA090578-060008
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Indoles; 0 / Ligands; 0 / Lymphokines; 0 / Platelet-Derived Growth Factor; 0 / Pyrroles; 0 / RNA, Small Interfering; 0 / platelet-derived growth factor C; 0 / sunitinib; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  • [Other-IDs] NLM/ NIHMS98241; NLM/ PMC2676215
  •  go-up   go-down


62. Kodama J, Shinyo Y, Hasengaowa, Kusumoto T, Seki N, Nakamura K, Hongo A, Hiramatsu Y: Loss of basement membrane heparan sulfate expression is associated with pelvic lymph node metastasis in invasive cervical cancer. Oncol Rep; 2005 Jul;14(1):89-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Basement Membrane / metabolism. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / metabolism. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Female. Gene Expression Regulation, Neoplastic. Glucuronidase / genetics. Glucuronidase / metabolism. Humans. Immunohistochemistry. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis


63. Dueñas-González A, Cetina-Perez L, Lopez-Graniel C, Gonzalez-Enciso A, Gómez-Gonzalez E, Rivera-Rubi L, Montalvo-Esquivel G, Muñoz-Gonzalez D, Robles-Flores J, Vazquez-Govea E, de La Garza J, Mohar A: Pathologic response and toxicity assessment of chemoradiotherapy with cisplatin versus cisplatin plus gemcitabine in cervical cancer: a randomized Phase II study. Int J Radiat Oncol Biol Phys; 2005 Mar 1;61(3):817-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To compare gemcitabine and cisplatin (GC) with cisplatin (C) concurrent with radiotherapy in International Federation of Gynecology and Obstetrics Stage IB2, IIA, and IIB cervical carcinoma in a preoperative setting.
  • [MeSH-minor] Adult. Aged. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Confidence Intervals. Female. Humans. Middle Aged. Radiotherapy Dosage


64. Fujita T, Fukuda K, Ohmura Y, Nishi H, Mano M, Komatsubara S, Doihara H, Shimizu N: Long-term survival of a patient with advanced adenosquamous carcinoma of the gallbladder after radical resection. J Hepatobiliary Pancreat Surg; 2005;12(2):147-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival of a patient with advanced adenosquamous carcinoma of the gallbladder after radical resection.
  • Patients with adenosquamous carcinoma of the gallbladder tend to present with a bulky tumor that frequently displays involvement with adjacent organs, and diagnosis is usually made at an advanced stage.
  • This may contribute to the poor prognosis of patients with adenosquamous carcinoma of the gallbladder compared to patients with adenocarcinoma.
  • We present herein a patient with advanced adenosquamous carcinoma of the gallbladder who is doing well with no evidence of recurrence more than 5 years after radical resection.
  • Gallbladder carcinoma was diagnosed, and radical resection, including partial gastrectomy, was performed.
  • Histopathologically, adenosquamous carcinoma was diagnosed, and it was graded as si, hinf0, binf0, pv0, a0, t4, n0, and stage IVa.
  • [MeSH-major] Carcinoma, Adenosquamous / surgery. Gallbladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868080.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


65. Paccagnella G, Ruggio F, Gizzo S, Nardelli GB: Human papillomavirus detection and genotyping on pelvic nodes in patients with synchronous gynecological malignancies: a tool for identifying the primary site of lymphatic spread? Int J Gynecol Cancer; 2010 Nov;20(8):1304-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Two women with synchronous squamous cervical and adenosquamous endometrial cancers (patient A) and squamous cervical and serous borderline ovarian tumors (patient B) entered retrospectively this study.
  • [MeSH-major] Diagnostic Techniques, Obstetrical and Gynecological. Genital Neoplasms, Female / diagnosis. Lymph Nodes / virology. Neoplasms, Multiple Primary / diagnosis. Neoplasms, Unknown Primary / diagnosis. Papillomavirus Infections / diagnosis. Papillomavirus Infections / virology
  • [MeSH-minor] Carcinoma, Adenosquamous / diagnosis. Carcinoma, Adenosquamous / etiology. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / virology. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / virology. DNA, Viral / analysis. Female. Genotype. Human papillomavirus 16 / genetics. Humans. Lymphatic Metastasis. Pelvis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21051969.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


66. Tan DJ, Chang J, Liu LL, Bai RK, Wang YF, Yeh KT, Wong LJ: Significance of somatic mutations and content alteration of mitochondrial DNA in esophageal cancer. BMC Cancer; 2006 Apr 18;6:93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The entire mitochondrial genome was screened for somatic mutations in 20 pairs (18 esophageal squamous cell carcinomas, one adenosquamous carcinoma and one adenocarcinoma) of tumor/surrounding normal tissue of esophageal cancers, using temporal temperature gradient gel electrophoresis (TTGE), followed by direct DNA sequencing to identify the mutations.
  • RESULTS: Fourteen somatic mtDNA mutations were identified in 55% (11/20) of tumors analyzed, including 2 novel missense mutations and a frameshift mutation in ND4L, ATP6 subunit, and ND4 genes respectively.
  • Some missense and frameshift mutations may play an important role in the tumorigenesis of esophageal carcinoma.

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Med Genet. 2004 May;41(5):e65 [15121793.001]
  • [Cites] Electrophoresis. 2004 Aug;25(15):2602-10 [15300781.001]
  • [Cites] Mol Cancer Res. 2004 Aug;2(8):433-41 [15328370.001]
  • [Cites] Nature. 1981 Apr 9;290(5806):457-65 [7219534.001]
  • [Cites] Annu Rev Cell Biol. 1988;4:289-333 [2461720.001]
  • [Cites] Int J Epidemiol. 1992 Oct;21(5):877-82 [1468848.001]
  • [Cites] Biochim Biophys Acta. 1995 May 24;1271(1):141-51 [7599200.001]
  • [Cites] Science. 1997 Feb 21;275(5303):1129-32 [9027314.001]
  • [Cites] Nat Genet. 1998 Nov;20(3):291-3 [9806551.001]
  • [Cites] Eur J Cancer. 1999 Feb;35(2):316-9 [10448277.001]
  • [Cites] Science. 2000 Feb 4;287(5454):848-51 [10657297.001]
  • [Cites] Science. 2000 Mar 17;287(5460):2017-9 [10720328.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4231-7 [10945635.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 1;92(21):1753-63 [11058618.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6822-5 [11156372.001]
  • [Cites] Int J Cancer. 2001 May 1;92(3):319-21 [11291064.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Jul;31(3):255-63 [11391796.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Jul;31(3):274-81 [11391798.001]
  • [Cites] Int J Cancer. 2001 Aug 15;93(4):534-8 [11477557.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):5998-6001 [11507041.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7623-6 [11606403.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):972-6 [11861366.001]
  • [Cites] Nat Genet. 2002 Apr;30(4):406-10 [11865300.001]
  • [Cites] Cancer Invest. 2002;20(4):557-69 [12094550.001]
  • [Cites] Clin Chem. 2002 Nov;48(11):1901-12 [12406974.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Jun;37(2):186-94 [12696067.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):3866-71 [12873974.001]
  • [Cites] J Med Genet. 2003 Nov;40(11):e125 [14627692.001]
  • [Cites] Int J Cancer. 2004 Jan 10;108(2):228-31 [14639607.001]
  • [Cites] Biochem J. 2004 Feb 15;378(Pt 1):17-20 [14683524.001]
  • [Cites] Mutat Res. 2004 Mar 22;547(1-2):71-8 [15013701.001]
  • [Cites] Br J Cancer. 2004 Jun 14;90(12):2390-6 [15150555.001]
  • [Cites] Carcinogenesis. 2004 Jul;25(7):1157-63 [14963017.001]
  • [Cites] BMC Cancer. 2004 Jul 1;4:30 [15230979.001]
  • [Cites] Electrophoresis. 2004 Aug;25(15):2593-601 [15300780.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1011:304-9 [15126306.001]
  • (PMID = 16620376.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA100023; United States / NCI NIH HHS / CA / R01CA100023; United States / NCI NIH HHS / CA / R21CA87327
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Mitochondrial; 0 / Reactive Oxygen Species; 9007-49-2 / DNA
  • [Other-IDs] NLM/ PMC1459869
  •  go-up   go-down


67. Kuwabara Y, Susumu N, Banno K, Hirao T, Kawaguchi M, Yamagami W, Suzuki N, Aoki D, Nozawa S: Clinical characteristics of prognostic factors in poorly differentiated (G3) endometrioid adenocarcinoma in Japan. Jpn J Clin Oncol; 2005 Jan;35(1):23-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics of prognostic factors in poorly differentiated (G3) endometrioid adenocarcinoma in Japan.
  • BACKGROUND: It has been reported that prognosis is less favorable in poorly (G3) differentiated endometrioid adenocarcinoma than in well (G1) or moderately (G2) differentiated endometrioid adenocarcinoma.
  • The goal of this study is therefore to analyze the prognosis of G3 endometrioid adenocarcinoma and various factors that may predict a favorable prognosis.
  • METHOD: This study included 699 Japanese cases of endometrioid adenocarcinoma at the International Federation of Gynaecology and Obstetrics (FIGO) surgical stages I-IV (including 74 G3 cases).
  • We investigated the G1-G3 survival rates of endometrioid adenocarcinoma cases and the G2 and G3 disease-free periods.
  • We also examined the clinicopathological characteristics of G3 endometrioid adenocarcinoma.
  • The absence of adnexal metastasis and low pre-surgery CA19-9 values may suggest a relatively favorable prognosis in G3 endometrioid adenocarcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / pathology. Cell Cycle. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Ovarian Neoplasms / secondary. Prognosis. Survival Rate. Uterine Cervical Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15681600.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


68. Seethala RR, Dacic S, Cieply K, Kelly LM, Nikiforova MN: A reappraisal of the MECT1/MAML2 translocation in salivary mucoepidermoid carcinomas. Am J Surg Pathol; 2010 Aug;34(8):1106-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A reappraisal of the MECT1/MAML2 translocation in salivary mucoepidermoid carcinomas.
  • The MECT1/MAML2 translocation is identified in a large proportion of mucoepidermoid carcinomas (MEC) of the salivary gland and is an emerging favorable prognosticator.
  • We analyzed 55 salivary MEC and 36 potential MEC mimics (24 Warthin tumors, 5 oncocytomas, 3 squamous cell carcinomas, 2 squamoid salivary duct carcinomas, 1 lymphoepithelial cyst, 1 Schneiderian carcinoma ex papilloma) for presence of the MECT1/MAML2 translocation by fluorescent in-situ hybridization (FISH) and real-time RT-PCR.
  • Translocation positive cases had a better disease-specific survival (log rank P=0.026) although 2 patients still died of disease.
  • There are 2 distinct subgroups within high-grade MEC, and the translocation negative tumors may actually be more appropriately categorized as another tumor type (such as adenosquamous carcinoma).
  • [MeSH-major] Carcinoma, Mucoepidermoid / genetics. Oncogene Proteins, Fusion / genetics. Salivary Gland Neoplasms / genetics. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Child. Disease-Free Survival. Female. Gene Expression Regulation, Neoplastic. Humans. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Time Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20588178.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P50 CA097190
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MECT1-MAML2 fusion protein, human; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


69. Toita T, Kodaira T, Uno T, Shinoda A, Akino Y, Mitsumori M, Teshima T: Patterns of pretreatment diagnostic assessment and staging for patients with cervical cancer (1999-2001): patterns of care study in Japan. Jpn J Clin Oncol; 2008 Jan;38(1):26-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Diagnostic Imaging / trends. Diagnostic Tests, Routine / trends. Oncology Service, Hospital / utilization. Process Assessment (Health Care) / trends. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / radiotherapy. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / diagnosis. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / radiotherapy. Cross-Sectional Studies. Female. Humans. Japan. Middle Aged. Neoplasm Invasiveness / diagnosis. Neoplasm Staging


70. Niwa Y, Matsuo K, Ito H, Hirose K, Tajima K, Nakanishi T, Nawa A, Kuzuya K, Tamakoshi A, Hamajima N: Association of XRCC1 Arg399Gln and OGG1 Ser326Cys polymorphisms with the risk of cervical cancer in Japanese subjects. Gynecol Oncol; 2005 Oct;99(1):43-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The cases comprised 131 cervical cancer patients: 87 cases with squamous cell carcinoma (SCC) and 44 with adenocarcinoma (ADC) or adenosquamous carcinoma (ADSC).
  • RESULTS: The frequency of the XRCC1 399GlnGln genotype was higher in individuals with adenocarcinoma/adenosquamous carcinoma than in the healthy controls (OR = 2.98, 95% CI = 1.11-8.01, P = 0.030).
  • In stratification analysis, significant elevated risk of adenocarcinoma/adenosquamous carcinoma was associated with the XRCC1 399GlnGln genotype among nonsmokers (OR = 3.85, 95% CI = 1.28-11.59, P = 0.017), but not among smokers.
  • CONCLUSION: This is the first report that the XRCC1 Arg399Gln polymorphism might be important in relation to the risk of adenocarcinoma/adenosquamous carcinoma of the cervix.
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / genetics. Adult. Aged. Aged, 80 and over. Alleles. Carcinoma, Adenosquamous / enzymology. Carcinoma, Adenosquamous / genetics. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / genetics. Case-Control Studies. Female. Genetic Predisposition to Disease. Humans. Japan. Middle Aged. Polymorphism, Genetic

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15990162.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / X-ray repair cross complementing protein 1; EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / oxoguanine glycosylase 1, human
  •  go-up   go-down


71. Tadokoro H, Shigihara T, Ikeda T, Takase M, Suyama M: Two distinct pathways of p16 gene inactivation in gallbladder cancer. World J Gastroenterol; 2007 Dec 21;13(47):6396-403
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Adenosquamous / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Gallbladder Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Gene Silencing. Genes, p16

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18081229.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16
  • [Other-IDs] NLM/ PMC4205459
  •  go-up   go-down


72. Kaneda M, Tarukawa T, Watanabe F, Adachi K, Sakai T, Nakabayashi H: Clinical features of primary lung cancer adjoining pulmonary bulla. Interact Cardiovasc Thorac Surg; 2010 Jun;10(6):940-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A few investigators have suggested a possible association between lung cancer and a pulmonary bulla.
  • In comparison with the control group, a ratio of squamous cell carcinoma (SCC) and large cell carcinoma was significantly high (P<0.05) and differentiation of the carcinoma was poor (P<0.001).
  • [MeSH-major] Blister / diagnosis. Carcinoma / diagnosis. Lung / pathology. Lung Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / diagnosis. Carcinoma, Large Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Cell Differentiation. Humans. Incidence. Japan / epidemiology. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Respiratory Function Tests. Retrospective Studies. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20299444.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


73. Okano T, Gemma A, Hosoya Y, Hosomi Y, Nara M, Kokubo Y, Yoshimura A, Shibuya M, Nagashima M, Harris CC, Kudoh S: Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer. Oncol Rep; 2006 Mar;15(3):545-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The ING1 gene is involved in the regulation of the cell cycle, senescence, and apoptosis and is a novel candidate tumor suppressor gene.
  • To determine whether an alteration in these genes plays a role in carcinogenesis and tumor progression in lung cancer, we screened 30 human lung cancer cell lines and 31 primary lung cancer tumors for mutations in these genes using polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) and direct sequencing.
  • We also examined the expression of ING1 and ING2 in lung cancer cell lines that either had or lacked a p53 mutation, and in a control bronchial epithelium cell line, using quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR).
  • ING1 expression was up-regulated in all 7 lung cancer cell lines that had a p53 mutation, while the expression of ING2 was down-regulated in 6 of 7 lung cancer cell lines that had a p53 mutation.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Base Sequence. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / pathology. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / pathology. Carcinoma, Small Cell / genetics. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Cell Line, Tumor. DNA Mutational Analysis. DNA, Neoplasm / chemistry. DNA, Neoplasm / genetics. Gene Expression Regulation, Neoplastic. Homeodomain Proteins / genetics. Humans. Intracellular Signaling Peptides and Proteins / genetics. Nuclear Proteins / genetics. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptors, Cytoplasmic and Nuclear / genetics. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16465410.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Homeodomain Proteins; 0 / ING1 protein, human; 0 / ING2 protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


74. Koshimune R, Aoe M, Toyooka S, Hara F, Ouchida M, Tokumo M, Sano Y, Date H, Shimizu N: Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines. BMC Cancer; 2007;7:8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines.
  • In this study, we investigate the anti-tumor effect of YM529 on non-small cell lung cancer (NSCLC).
  • METHODS: Direct anti-tumor effect of YM529 against 8 NSCLC cell lines (adenocarcinoma: H23, H1299, NCI-H1819, NCI-H2009, H44, A549, adenosquamous cell carcinoma: NCI-H125, squamous cell carcinoma: NCI-H157) were measured by MTS assay and calculated inhibition concentration 50 % (IC50) values.
  • RESULTS: We found that there was direct anti-tumor effect of YM529 on 8 NSCLC cell lines in a dose-dependent manner and their IC50 values were 2.1 to 7.9 microM and YM529 induced apoptosis and G1 arrest cell cycle with dose-dependent manner and YM529 caused down regulation of phospholyration of ERK1/2 in signaling pathways of NSCLC cell line (NCI-H1819).
  • CONCLUSION: Our study demonstrate that YM529 showed direct anti-tumor effect on NSCLC cell lines in vitro, which supports the possibility that third-generation BPs including YM529 can be one of therapeutic options for NSCLC.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Non-Small-Cell Lung / drug therapy. Diphosphonates / pharmacology. Imidazoles / pharmacology. Lung Neoplasms / drug therapy
  • [MeSH-minor] Apoptosis / drug effects. Cell Cycle / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Humans


75. Kasamatsu T, Onda T, Yamada T, Tsunematsu R: Clinical aspects and prognosis of pelvic recurrence of cervical carcinoma. Int J Gynaecol Obstet; 2005 Apr;89(1):39-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical aspects and prognosis of pelvic recurrence of cervical carcinoma.
  • OBJECTIVE: To identify which patients with locally recurrent cervical carcinoma are potentially curable.
  • All 43 patients with pelvic wall recurrence developed progressive disease.
  • [MeSH-major] Neoplasm Recurrence, Local / therapy. Pelvic Neoplasms / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Adenocarcinoma / therapy. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / diagnosis. Carcinoma, Adenosquamous / secondary. Carcinoma, Adenosquamous / therapy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Female. Humans. Middle Aged. Neoplasm Staging. Pelvic Exenteration. Prognosis. Radiotherapy. Retrospective Studies. Survival Analysis. Treatment Outcome


76. Geyer FC, Lambros MB, Natrajan R, Mehta R, Mackay A, Savage K, Parry S, Ashworth A, Badve S, Reis-Filho JS: Genomic and immunohistochemical analysis of adenosquamous carcinoma of the breast. Mod Pathol; 2010 Jul;23(7):951-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic and immunohistochemical analysis of adenosquamous carcinoma of the breast.
  • Breast adenosquamous carcinomas are rare tumours characterized by well-developed gland formation intimately admixed with solid nests of squamous cells immersed in a highly cellular spindle cell stroma.
  • Here we studied five cases of adenosquamous carcinomas to determine their genetic profiles and to investigate whether the spindle cell component of these cancers could at least in part stem from the glandular/epithelial components.
  • Five adenosquamous carcinomas of the breast were subjected to (1) immunohistochemical analysis, (2) microdissection and genetic analysis with a high-resolution microarray comparative genomic hybridization platform, and (3) chromogenic in situ hybridization.
  • In conclusion, breast adenosquamous carcinomas are triple-negative cancers that express 'basal' keratins.
  • Some of the spindle cells in adenosquamous carcinomas are derived from the epithelial component, suggesting that adenosquamous carcinomas may also be part of the group of metaplastic breast carcinomas with spindle cell metaplastic elements.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20453835.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


77. Demir G, Yanmaz T, Celik AF, Ozbay G, Serdengecti S: Primary adenosquamous carcinoma of the liver: case with the longest survival. J Clin Gastroenterol; 2005 Nov-Dec;39(10):924-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adenosquamous carcinoma of the liver: case with the longest survival.
  • [MeSH-major] Carcinoma, Adenosquamous / diagnosis. Liver Neoplasms / diagnosis
  • [MeSH-minor] Adult. Disease-Free Survival. Humans. Male

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16208126.001).
  • [ISSN] 0192-0790
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


78. Goff LW, Rothenberg ML, Lockhart AC, Roth BJ, VerMeulen WL, Chan E, Berlin JD: A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies. Am J Clin Oncol; 2008 Oct;31(5):413-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three patients with colon cancer, 1 patient with renal cell cancer and 1 patient with adenosquamous cell carcinoma of the ethmoid sinus had stable disease.
  • [MeSH-minor] Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Disease-Free Survival. Epirubicin / administration & dosage. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Salvage Therapy. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18838875.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


79. Pathak KA, Nason RW, Talole SD, Abdoh AA: Are buccal cancers in India and Canada any different? J Surg Oncol; 2008 May 1;97(6):529-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND OBJECTIVE: To compare the treatment outcomes of squamous cell carcinoma (SCC) of buccal mucosa in India and Canada.
  • Radiated patients had three times higher risk of dying of disease than surgically treated ones (HR = 3.03; 95% CI = 1.64, 5.60; P < 0.001).
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Mouth Mucosa / pathology. Mouth Neoplasms / epidemiology
  • [MeSH-minor] Aged. Canada / epidemiology. Carcinoma, Adenosquamous / epidemiology. Cohort Studies. Female. Humans. India / epidemiology. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18335452.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. dos Reis R, Frumovitz M, Milam MR, Capp E, Sun CC, Coleman RL, Ramirez PT: Adenosquamous carcinoma versus adenocarcinoma in early-stage cervical cancer patients undergoing radical hysterectomy: an outcomes analysis. Gynecol Oncol; 2007 Dec;107(3):458-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma versus adenocarcinoma in early-stage cervical cancer patients undergoing radical hysterectomy: an outcomes analysis.
  • OBJECTIVE: To evaluate whether histology (adenocarcinoma versus adenosquamous carcinoma) is an independent prognostic indicator in patients with stage IB1 cervical cancer after radical hysterectomy.
  • METHODS: All patients with adenocarcinoma or adenosquamous carcinoma who underwent radical hysterectomy between October 1990 and December 2006 at The University of Texas M. D.
  • Clinico-pathological data collected included age, disease stage, tumor grade, lymph node status, parametrial involvement, depth of invasion, evidence of lymph-vascular space invasion (LVSI), and adjuvant therapy.
  • Patients were categorized as having "low-risk" or "high-risk" disease depending on the final pathologic findings.
  • RESULTS: We identified 126 patients with stage IB1 adenosquamous (n=29) or adenocarcinoma (n=97) cervical cancer.
  • The median age was 40.3 years for patients with adenocarcinoma and 35.2 years for patients with adenosquamous carcinoma (P=0.88).
  • Grade III histology and LVSI were more common in patients with adenosquamous tumors than in patients with adenocarcinoma (85% versus 16%; P<0.01 and 56.5% versus 32.8; P=0.04).
  • There was no difference in recurrence rates between the two histologic groups, but the time to recurrence was shorter for patients with adenosquamous carcinoma (7.9 months versus 15 months; P=0.01).
  • There was no difference between cell types with regards to recurrence and recurrence-free survival rates in the low- and high-risk groups.
  • CONCLUSION: We found no evidence that histologic subtype affects outcome; however, the median time to recurrence was shorter in patients with adenosquamous carcinoma.
  • Our study suggests that in patients with stage IB1 adenosquamous carcinoma or adenocarcinoma, the presence of high-risk features is more important than histologic subtype.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / surgery. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / surgery


81. Ballester M, Dubernard G, Rouzier R, Barranger E, Darai E: Use of the sentinel node procedure to stage endometrial cancer. Ann Surg Oncol; 2008 May;15(5):1523-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Lymph node status is a major prognostic factor and a criterion for adjuvant therapy in endometrial cancer.
  • Among the ten women with a positive SN, three of the four women with a grade 1 tumour at biopsy had grade 2-3 disease on final histology.
  • Given the limited capacity of MR imaging to detect myometrial invasion, and of biopsy to determine histological grade, our results support the systematic use of the SN procedure in women with endometrial cancer, including those with presumed early-stage disease and/or well-differentiated tumours.
  • [MeSH-major] Adenocarcinoma / secondary. Endometrial Neoplasms / pathology. Lymph Nodes / pathology. Sentinel Lymph Node Biopsy / methods
  • [MeSH-minor] Adenocarcinoma, Clear Cell / epidemiology. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Clear Cell / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Adenosquamous / secondary. Carcinoma, Adenosquamous / surgery. Carcinoma, Papillary / epidemiology. Carcinoma, Papillary / secondary. Carcinoma, Papillary / surgery. Cystadenocarcinoma, Serous / epidemiology. Cystadenocarcinoma, Serous / secondary. Cystadenocarcinoma, Serous / surgery. False Negative Reactions. Female. Humans. Lymphatic Metastasis. Magnetic Resonance Imaging. Middle Aged. Neoplasm Staging. Prognosis. Risk Factors. Survival Rate

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2008 Jul;15(7):1815-7 [18473144.001]
  • (PMID = 18322758.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Hammouda D, Muñoz N, Herrero R, Arslan A, Bouhadef A, Oublil M, Djedeat B, Fontanière B, Snijders P, Meijer C, Franceschi S: Cervical carcinoma in Algiers, Algeria: human papillomavirus and lifestyle risk factors. Int J Cancer; 2005 Jan 20;113(3):483-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical carcinoma in Algiers, Algeria: human papillomavirus and lifestyle risk factors.
  • A total of 198 cervical carcinoma (CC) cases (including 15 adeno- and adenosquamous carcinomas) and 202 age-matched control women were included.
  • [MeSH-major] Adenocarcinoma. Carcinoma, Adenosquamous. Papillomaviridae / isolation & purification. Papillomavirus Infections / epidemiology. Uterine Cervical Neoplasms

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15455386.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


83. Silva AR: Remarkably high frequency of EGFR expression in breast carcinomas with squamous differentiation. Int J Surg Pathol; 2006 Jul;14(3):268; author reply 269
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remarkably high frequency of EGFR expression in breast carcinomas with squamous differentiation.
  • [MeSH-major] Breast Neoplasms / metabolism. Carcinoma, Adenosquamous / metabolism. Carcinoma, Squamous Cell / metabolism. Cell Transformation, Neoplastic / metabolism. Membrane Proteins / metabolism. Receptor, Epidermal Growth Factor / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Int J Surg Pathol. 2005 Oct;13(4):319-27 [16273187.001]
  • (PMID = 16959717.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


84. Yi L, Wang Y: [Mixed prostatic carcinoma: a report of 5 patients and literature review]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Jul;34(7):646-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mixed prostatic carcinoma: a report of 5 patients and literature review].
  • OBJECTIVE: To improve the awareness of rare mixed prostatic carcinoma.
  • METHODS: We reviewed the clinical data of 5 patients with prostatic mixed tumor and relevant literature to explore diagnosis and treatment for it.
  • RESULTS: Patient 1 with mixed small cell carcinoma and adenocarcinoma of the prostate who underwent transurethral electrovaporization of the prostate (TUVP) and flumamide therapy died of lung metastasis 7 months later.
  • Patient 2 with mixed small cell carcinoma and adenocarcinoma of the prostate who underwent TUVP and bilateral testicular resection died of lung metastasis 10 months later.
  • Patient 3 with adenosquamous carcinoma of the prostate who underwent TUVP, radiation therapy and flumamide therapy died of multiple organ failure 8 months later because of the lung, liver, and multiple bone metastasis.
  • Patient 4 with prostatic adenosquamous carcinoma who underwent cystoprostatectomy combined with urinary diversion has already survived for 1 year.
  • CONCLUSION: Mixed prostatic carcinoma is quite aggressive with bad prognosis.
  • Its diagnosis relies on detailed pathological examination and immunohistochemical techniques.
  • Patients with prostate adenocarcinoma should be followed up timely after endocrine treatment or radiotherapy.
  • Radical surgery is most effective for mixed prostatic carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Adenosquamous / pathology. Carcinoma, Small Cell / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19648679.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] China
  •  go-up   go-down


86. Yin R, Xu L, Ren B, Jiang F, Fan X, Zhang Z, Li M, Hu Z: Clinical experience of lobectomy with pulmonary artery reconstruction for central non-small-cell lung cancer. Clin Lung Cancer; 2010 Mar 1;11(2):120-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical experience of lobectomy with pulmonary artery reconstruction for central non-small-cell lung cancer.
  • Patients with pN0 disease also had greater 5-year survival than patients with pN2-3 disease (71% vs. 9%; P = .004).
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Adenosquamous / surgery. Carcinoma, Non-Small-Cell Lung / surgery. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / surgery. Pneumonectomy. Pulmonary Artery / surgery


87. Nagy PS, Sipos J: [Glassy cell carcinoma of the endometrium: case report and review of the literature]. Orv Hetil; 2009 Jun 21;150(25):1173-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Glassy cell carcinoma of the endometrium: case report and review of the literature].
  • The authors presented a case of a 68-year-old woman with glassy cell carcinoma of the endometrium in FIGO stage IA, treated with hysterectomy, bilateral salpingo-oophorectomy and radiation therapy.
  • The patient was alive and disease free at the end of 2 years of follow up.
  • Glassy cell carcinoma of the endometrium is a rare neoplasm, with 13 previously cases reported in the literature.
  • Although glassy cell carcinoma is considered to be a poor differentiated variant of adenosquamous carcinoma, its real nature is still debated.
  • In order to establish correct prognosis for this rare entity and to evaluate the nature and clinical significance of glassy cell carcinoma detailed analysis of more cases is required.
  • [MeSH-major] Carcinoma, Adenosquamous / diagnosis. Carcinoma, Adenosquamous / therapy. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19497839.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Number-of-references] 15
  •  go-up   go-down


88. Lim SH, Yang HW, Kim A, Cha SW, Jung SH, Go H, Lee WC: Adenosquamous carcinoma of extrahepatic bile duct: a case report. Korean J Intern Med; 2007 Sep;22(3):206-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of extrahepatic bile duct: a case report.
  • Most malignant tumors originating from the biliary tract are adenocarcinomas, and adenosqamous carcinoma of Klatskin's tumor is a very rare finding.
  • The histopathologic findings showed adenosquamous carcinoma.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Bile Ducts, Extrahepatic. Carcinoma, Adenosquamous / diagnosis. Palliative Care

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1357-65 [14630274.001]
  • [Cites] J Surg Oncol. 1986 Oct;33(2):140-2 [3531727.001]
  • [Cites] Cancer. 1992 Jul 15;70(2):415-22 [1319814.001]
  • [Cites] J Gastroenterol Hepatol. 1993 Nov-Dec;8(6):607-12 [8280849.001]
  • [Cites] Hepatogastroenterology. 1996 May-Jun;43(9):663-6 [8799412.001]
  • [Cites] Radiother Oncol. 1996 Oct;41(1):61-6 [8961369.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):105-12 [12909222.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 4:215-20 [10436826.001]
  • [Cites] J Gastroenterol. 2005 Feb;40(2):192-9 [15770404.001]
  • [Cites] Korean J Hepatol. 2005 Mar;11(1):86-9 [15788889.001]
  • [Cites] World J Gastroenterol. 2006 Jan 7;12(1):119-22 [16440429.001]
  • [Cites] Korean J Gastroenterol. 2006 Aug;48(2):132-6 [16929159.001]
  • [Cites] Australas Radiol. 1997 May;41(2):151-4 [9153812.001]
  • (PMID = 17939340.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2687689
  •  go-up   go-down


89. Takac I, Ursic-Vrscaj M, Repse-Fokter A, Kodric T, Rakar S, Mozina A, Smrkolj S, Primic-Zakelj M, Strzinar V, Vakselj A, Arko D: Clinicopathological characteristics of cervical cancer between 2003 and 2005, after the introduction of a national cancer screening program in Slovenia. Eur J Obstet Gynecol Reprod Biol; 2008 Sep;140(1):82-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They were stratified for stage, tumor characteristics and treatment methods according to gynecologic examination attendance in the last 5 years preceding the diagnosis of CC (attenders vs. nonattenders).
  • RESULTS: In the period of observation, 242 women (53.8%) visited their gynecologists in the 5-year period prior to diagnosis of CC.
  • Squamous cell carcinoma was present in 378 women (84.0%), adenocarcinoma in 45 (10.0%), adenosquamous carcinoma in 24 (5.3%) and other types in 3 women (0.7%).
  • Attenders were significantly more frequently diagnosed with squamous cell carcinoma than nonattenders (chi-square=5.13; P<0.05).
  • [MeSH-major] Carcinoma / epidemiology. Uterine Cervical Neoplasms / epidemiology


90. Akatsu T, Kameyama K, Kawachi S, Tanabe M, Aiura K, Wakabayashi G, Ueda M, Shimazu M, Kitajima M: Gallbladder carcinoma with osteoclast-like giant cells. J Gastroenterol; 2006 Jan;41(1):83-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gallbladder carcinoma with osteoclast-like giant cells.
  • Recently, some authors have suggested that carcinomas containing OGCs may represent a distinct clinicopathological entity with a more favorable prognosis.
  • We report here on an additional case of gallbladder carcinoma with an infiltrate of OGCs.
  • Histological examination showed an adenosquamous carcinoma with an infiltrate of benign OGCs.
  • This case adds to a small body of literature on gallbladder carcinoma with OGCs.
  • Further studies are required to clearly define the prognostic significance of these giant cells in gallbladder cancer and the differences between adenosquamous carcinoma with OGCs and other gallbladder carcinomas (such as adenocarcinoma and squamous cell carcinoma) with those cells.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Gallbladder Neoplasms / pathology. Giant Cells / pathology. Osteoclasts / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Prognosis

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 1995 Apr;103(4):453-9 [7726143.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Sep;87(18):7260-4 [2169622.001]
  • [Cites] Pathol Int. 2003 Jul;53(7):450-6 [12828610.001]
  • [Cites] Breast. 2001 Jun;10(3):231-6 [14965590.001]
  • [Cites] Endocrinology. 1989 Jul;125(1):20-7 [2544401.001]
  • [Cites] Am J Gastroenterol. 1999 Jun;94(6):1678-81 [10364044.001]
  • [Cites] Cancer. 1988 May 1;61(9):1872-9 [2451557.001]
  • [Cites] Arch Pathol Lab Med. 1981 Jun;105(6):287-93 [6263212.001]
  • [Cites] Hum Pathol. 1992 Jun;23(6):703-6 [1592394.001]
  • [Cites] Pathol Res Pract. 1993 Mar;189(2):228-31; discussion 232-4 [8321752.001]
  • [Cites] Am J Gastroenterol. 1995 Jul;90(7):1177-9 [7611227.001]
  • (PMID = 16501862.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


91. Nagai T, Okubo T, Sakaguchi R, Seki H, Takeda S: Glassy cell carcinoma of the uterine cervix responsive to neoadjuvant intraarterial chemotherapy. Int J Clin Oncol; 2008 Dec;13(6):541-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glassy cell carcinoma of the uterine cervix responsive to neoadjuvant intraarterial chemotherapy.
  • Described as a poorly differentiated adenosquamous cancer, glassy cell carcinoma of the uterine cervix is a rare disease considered to have an extremely poor prognosis.
  • We report a patient with glassy cell carcinoma of the uterine cervix who responded to NAC, and we discuss this case with reference to reports in the literature.
  • The patient was admitted to our center following the diagnosis of stage IIb cervical cancer (glassy cell carcinoma), to await fetal development, and an elective cesarean section was performed at slightly more than 29 gestational weeks.
  • It has been 6 years, to date, since the initial treatment, and our patient is alive and disease/recurrence free.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Uterine Cervical Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Cancer. 2003 May-Jun;13(3):308-12 [12801261.001]
  • [Cites] Gynecol Oncol. 1992 Mar;44(3):254-9 [1541437.001]
  • [Cites] Gynecol Oncol. 1997 Oct;67(1):61-9 [9345358.001]
  • [Cites] Am J Clin Pathol. 1991 Oct;96(4):520-8 [1716415.001]
  • [Cites] Gynecol Oncol. 1979 Oct;8(2):141-51 [499922.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2005 Aug;19(4):611-30 [15886059.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Mar;49(3):256-60 [11935219.001]
  • [Cites] Cancer. 1976 May;37(5):2238-46 [1260713.001]
  • [Cites] Lancet. 2000 Apr 1;355(9210):1159-60 [10791384.001]
  • [Cites] Cancer. 1956 Sep-Oct;9(5):971-9 [13364884.001]
  • [Cites] Semin Oncol. 2000 Feb;27(1 Suppl 1):23-7 [10697040.001]
  • [Cites] Aust N Z J Obstet Gynaecol. 1995 Nov;35(4):408-12 [8717566.001]
  • (PMID = 19093183.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


92. Chaux A, Lezcano C, Cubilla AL, Tamboli P, Ro J, Ayala A: Comparison of subtypes of penile squamous cell carcinoma from high and low incidence geographical regions. Int J Surg Pathol; 2010 Aug;18(4):268-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of subtypes of penile squamous cell carcinoma from high and low incidence geographical regions.
  • There is a worldwide geographical variation in the incidence of penile squamous cell carcinoma (PSCC); some subtypes are HPV-related (warty, basaloid) while others (keratinizing variants) are not.
  • The distribution of subtypes in the Paraguayan and the American series was: usual, 49.3 and 46.5%; verrucous, 8.3 and 7.6%; papillary NOS, 7.6 and 5.7%; warty, 6.9 and 8.3%; basaloid, 4.2 and 7.0%; sarcomatoid, 0.7 and 0.6%; adenosquamous, 3.5 and 0.6%; and mixed, 19.4 and 23.6%, respectively.
  • The distribution of mixed PSCC was: warty-basaloid, 50.0 and 59.5%; usual-verrucous, 21.4 and 21.6%; usual-warty, 14.3 and 8.1%; usual-basaloid, 7.1 and 0.0%; usual-papillary, 3.6 and 5.4%; and others, 3.6 and 5.4%, respectively.
  • In conclusion, we found no geographical difference in the incidence of histological subtypes (p = 0.6501), mixed PSCC (p = 0.5937) or HPV-related tumors (p = 0.2505).
  • Geographical variation may be the result of staging variation at clinical presentation or of pathological diagnosis.
  • The tendency for typical SCC to mix with verrucous and papillary carcinomas and of the basaloid to preferentially mix with benign condyloma and condylomatous (warty) carcinomas would support the hypothesis of the existence of an etiologically different dual population of penile tumors.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Papillomavirus Infections / pathology. Penile Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Verrucous / epidemiology. Carcinoma, Verrucous / pathology. Carcinoma, Verrucous / virology. Condylomata Acuminata / pathology. Condylomata Acuminata / virology. Humans. Incidence. Male. Neoplasm Invasiveness. Papillomaviridae / isolation & purification. Paraguay / epidemiology. Precancerous Conditions. Retrospective Studies. United States / epidemiology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19578046.001).
  • [ISSN] 1940-2465
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Khunamornpong S, Siriaunkgul S, Manusirivithaya S, Settakorn J, Srisomboon J, Ponjaroen J, Thorner PS: Prognostic value of p53 expression in early stage cervical carcinoma treated by surgery. Asian Pac J Cancer Prev; 2008 Jan-Mar;9(1):48-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of p53 expression in early stage cervical carcinoma treated by surgery.
  • OBJECTIVE: To evaluate the prognostic significance of p53 protein expression in patients with early stage cervical carcinoma treated by surgery alone in a well-controlled study.
  • METHODS: A matched case-control study was performed in patients with stage Ib-IIa cervical carcinoma who underwent radical hysterectomy with pelvic lymphadenectomy.
  • Cases included 30 patients who had tumor recurrence within 5 years after surgery; controls included 60 patients who were disease-free for at least 5 years after surgery.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Adenosquamous / metabolism. Carcinoma, Squamous Cell / metabolism. Hysterectomy. Lymph Node Excision. Tumor Suppressor Protein p53 / metabolism. Uterine Cervical Neoplasms / metabolism


94. Yi L, Yang LY, Wang YH: [Diagnosis and treatment of rare mixed prostatic carcinoma]. Zhonghua Nan Ke Xue; 2009 Aug;15(8):727-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of rare mixed prostatic carcinoma].
  • OBJECTIVE: To discuss the diagnosis and treatment of rare mixed prostatic carcinoma.
  • METHODS: We retrospectively analyzed the clinical data of 6 cases of mixed prostatic tumor confirmed by surgery or transrectal ultrasound guided prostate biopsy, and reviewed the related literature.
  • RESULTS: Three of the patients (2 with mixed small cell carcinoma and adenocarcinoma and 1 with adenosquamous carcinoma of the prostate) underwent palliative transurethral electrovaporization of the prostate (TUVP) and endocrine therapy, but all died within 7 - 10 months.
  • The other 3 (2 with adenosquamous carcinoma and 1 with carcinosarcoma of the prostate) received cystoprostatectomy, urinary diversion, pelvic lymphadenectomy and radiation therapy, and survived for more than 12 months, with 2 of them still under the follow-up observation.
  • CONCLUSION: Mixed prostatic carcinoma behaves aggressively with poor prognosis, of which the diagnosis relies on meticulous pathological examination and immunohistochemical techniques, and the most effective treatment is radical surgery.
  • [MeSH-major] Carcinoma, Adenosquamous / diagnosis. Carcinoma, Adenosquamous / surgery. Carcinosarcoma / diagnosis. Carcinosarcoma / surgery. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19852276.001).
  • [ISSN] 1009-3591
  • [Journal-full-title] Zhonghua nan ke xue = National journal of andrology
  • [ISO-abbreviation] Zhonghua Nan Ke Xue
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


95. Martinho O, Gonçalves A, Moreira MA, Ribeiro LF, Queiroz GS, Schmitt FC, Reis RM, Longatto-Filho A: KIT activation in uterine cervix adenosquamous carcinomas by KIT/SCF autocrine/paracrine stimulation loops. Gynecol Oncol; 2008 Nov;111(2):350-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KIT activation in uterine cervix adenosquamous carcinomas by KIT/SCF autocrine/paracrine stimulation loops.
  • OBJECTIVES: Uterine adenosquamous carcinoma (ASC) is an uncommon, yet, one of the most aggressive cervical cancer subtype.
  • METHODS: In a series of 30 cases, we studied KIT (CD117), KIT phosphorylated/activated form, as well as KIT ligand, stem cell factor (SCF), by immunohistochemistry.
  • [MeSH-major] Carcinoma, Adenosquamous / enzymology. Proto-Oncogene Proteins c-kit / metabolism. Stem Cell Factor / metabolism. Uterine Cervical Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18708242.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Stem Cell Factor; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


96. Qin Y, Peng Z, Lou J, Liu H, Deng F, Zheng Y: Discrepancies between clinical staging and pathological findings of operable cervical carcinoma with stage IB-IIB: a retrospective analysis of 818 patients. Aust N Z J Obstet Gynaecol; 2009 Oct;49(5):542-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discrepancies between clinical staging and pathological findings of operable cervical carcinoma with stage IB-IIB: a retrospective analysis of 818 patients.
  • METHODS: We collected retrospective data from 818 patients with cervical carcinoma staged IB-IIB, who were treated with primary surgery from January 1999 to June 2007.
  • The accuracy of pelvic examination to determine vaginal and parametrial disease was 70.2% and 74.0%, respectively.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / pathology. Physical Examination. Uterine Cervical Neoplasms / pathology


97. Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M, Nakanishi Y, Tsuchiya R, Shimokata K, Inoue H, Nukiwa T, Miyaoka E, Japanese Joint Committee of Lung Cancer Registry: A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol; 2008 Jan;3(1):46-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The data of 13,010 patients with only lung carcinoma histology (97.6%) were analyzed in terms of prognosis and clinicopathologic characteristics.
  • For the small cell histology (n = 390), the 5-year survival rates according to clinical (c) and pathologic (p) stages were as follows: 58.8% (n = 161) and 58.3% (n = 127) for IA, 58.0% (n = 77) and 60.2% (n = 79) for IB, 47.1% (n = 17) and 40.6% (n = 29) for IIA, 25.3% (n = 38) and 41.1% (n = 29) for IIB, 29.0% (n = 61) and 28.3% (n = 60) for IIIA, 36.3% (n = 19) and 34.6% (n = 40) for IIIB, and 27.8% (n = 12) and 30.8% for IV (n = 13).
  • For the non-small cell histology (n = 12,620), the 5-year survival rates according to c-stage and p-stage were as follows: 77.3% (n = 5642) and 83.9% (n = 4772) for IA, 59.8% (n = 3081) and 66.3% (n = 2629) for IB, 54.1% (n = 205) and 61.0% (n = 361) for IIA, 43.9% (n = 1227) and 47.4% (n = 1330) for IIB, 38.3% (n = 1628) and 32.8% (n = 1862) for IIIA, 32.6% (n = 526) and 29.6% (n = 1108) for IIIB, and 26.5% (n = 198) and 23.1% (n = 375) for IV.
  • Adenocarcinoma, female gender, and age less than 50 years were significant favorable prognostic factors.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Registries
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / pathology. Aged. Carcinoma, Adenosquamous / diagnosis. Carcinoma, Adenosquamous / pathology. Carcinoma, Large Cell / diagnosis. Carcinoma, Large Cell / pathology. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Female. Follow-Up Studies. Hospitals, Teaching. Humans. Japan. Male. Middle Aged. Models, Biological. Neoplasm Staging. Prognosis. Reproducibility of Results. Retrospective Studies. Surveys and Questionnaires. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18166840.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Zijlmans HJ, Fleuren GJ, Baelde HJ, Eilers PH, Kenter GG, Gorter A: Role of tumor-derived proinflammatory cytokines GM-CSF, TNF-alpha, and IL-12 in the migration and differentiation of antigen-presenting cells in cervical carcinoma. Cancer; 2007 Feb 1;109(3):556-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of tumor-derived proinflammatory cytokines GM-CSF, TNF-alpha, and IL-12 in the migration and differentiation of antigen-presenting cells in cervical carcinoma.
  • METHODS: In 90 patients with cervical carcinoma the number of monocytes/tumor-associated macrophages (TAM), mature dendritic cells (DC), and Langerhans cells (LHC) was determined using immunohistochemistry.
  • The expression of GM-CSF, TNF-alpha, and IL-12p40 did not correlate significantly with disease-free survival.
  • CONCLUSIONS: The results suggest that GM-CSF as well as TNF-alpha, produced by cervical carcinoma cells, may play a role in the differentiation of monocytes into mature DC.
  • [MeSH-major] Antigen-Presenting Cells / immunology. Cell Differentiation. Cell Movement. Granulocyte-Macrophage Colony-Stimulating Factor / metabolism. Interleukin-12 Subunit p40 / metabolism. Tumor Necrosis Factor-alpha / metabolism. Uterine Cervical Neoplasms / immunology
  • [MeSH-minor] Adenocarcinoma / immunology. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Adenosquamous / immunology. Carcinoma, Adenosquamous / metabolism. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / immunology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Dendritic Cells / immunology. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization. Langerhans Cells / immunology. Macrophages / immunology. Middle Aged. Monocytes / immunology. RNA Probes. Survival Rate

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society.
  • (PMID = 17177206.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-12 Subunit p40; 0 / RNA Probes; 0 / Tumor Necrosis Factor-alpha; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


99. Martínez-Monge R, Nagore G, Cambeiro M, Garrán C, Villafranca E, Jurado M: Intravaginal 1-week high-dose-rate brachytherapy alone for Stages I-II endometrial cancer. Brachytherapy; 2007 Jul-Sep;6(3):195-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND MATERIALS: From December 1999 to February 2005, 50 patients with International federation of gynecology and obstetrics Stages IA-IIB endometrioid endometrial adenocarcinoma were treated with total abdominal hysterectomy and bilateral salpingo-oophorectomy followed by postoperative HDR brachytherapy alone.
  • RESULTS: After a median followup of 37 months (range 12-80), the overall survival and disease-free survival were 96%.
  • [MeSH-major] Adenocarcinoma, Clear Cell / radiotherapy. Brachytherapy / methods. Carcinoma, Adenosquamous / radiotherapy. Endometrial Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17681240.001).
  • [ISSN] 1538-4721
  • [Journal-full-title] Brachytherapy
  • [ISO-abbreviation] Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Selvaggi L, Loizzi V, DI Gilio AR, Nardelli C, Cantatore C, Cormio G: Neoadjuvant chemotherapy in cervical cancer: a 67 patients experience. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):631-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sixty-seven patients received neoadjuvant chemotherapy: 34 had stage I disease, 28 had stage II disease, and 5 had stage III disease.
  • Clinical response to neoadjuvant chemotherapy occurred in 61 patients, including six with complete and 55 with partial response; five women showed stable disease and one progressed.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Squamous Cell / drug therapy. Neoadjuvant Therapy. Uterine Cervical Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681738.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 7673326042 / irinotecan; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; XT3Z54Z28A / Camptothecin
  •  go-up   go-down






Advertisement